e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 2, 2005
MannKind Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50865
|
|
13-3607736 |
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
|
|
|
28903 North Avenue Paine |
|
|
Valencia, California
|
|
91355 |
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (661) 775-5300
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 1.01 Entry into a Material Definitive Agreement.
On
August 2, 2005, MannKind Corporation, a Delaware corporation
(MannKind), entered into a
Securities Purchase Agreement with the purchasers set forth on
Exhibit A thereto (the Securities
Purchase Agreement), pursuant to which MannKind sold, at the closing on August 5, 2005, 17,131,682
shares of its common stock (the Shares) and warrants to purchase 3,426,340 shares of its common
stock (the Warrants) resulting in aggregate gross proceeds to MannKind of approximately $175.0
million (the Private Placement). The Warrants have an exercise price of $12.228 per share,
become exercisable 180 days after the closing of the Private Placement and expire on August 5,
2010. Under the terms of the Securities Purchase Agreement, MannKind has agreed to file, within 30
days after the closing of the Private Placement, a registration statement with the United States
Securities and Exchange Commission (the SEC) to register for resale the Shares and the shares of
MannKinds common stock issuable upon the exercise of the Warrants, and MannKind has agreed to use
its best efforts to cause such registration statement to be declared effective by the SEC within
(i) 60 days following the closing if the registration statement is not reviewed by the SEC, or (ii)
120 days following the closing if the registration statement is reviewed by the SEC.
MannKinds Chairman of the Board and Chief Executive Officer, Alfred E. Mann, who, with his
affiliated entities, holds more than 5% of MannKinds
outstanding capital stock, purchased approximately
$87.34 million in the Private Placement. Kent Kresa, a
director of MannKind, and Hakan S. Edstrom, MannKinds President and Chief Operating Officer,
collectively purchased an aggregate of approximately $157,000 in the Private Placement.
The foregoing is a summary of the terms of the Securities Purchase Agreement, does not purport
to be complete and is qualified in its entirety by reference to the full text of the Securities
Purchase Agreement, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by
reference.
Item 3.02 Unregistered Sales of Equity Securities.
On August 5, 2005, MannKind completed a private placement of the Shares and Warrants.
Pursuant to the terms of the Securities Purchase Agreement, MannKind sold 17,131,682 shares of its
common stock and warrants to purchase 3,426,340 shares of its common stock. The exercise price of
the Warrants is $12.228 per share. The Securities Purchase Agreement, including the form of
Warrant and other exhibits thereto, is attached hereto as Exhibit 99.1 and incorporated herein by
reference.
The aggregate offering price of the shares of Common Stock sold was approximately $175.0
million and the aggregate placement agent commissions were approximately $4.4 million. Wachovia
Capital Markets, LLC and Leerink Swann & Co. acted as MannKinds placement agents for the Shares
and Warrants issued in the Private Placement to purchasers other than Alfred E. Mann, Kent Kresa
and Hakan S. Edstrom.
The offering was made only to accredited investors, as such term is defined in Rule 501 of
Regulation D promulgated under the Securities Act of 1933, as amended (the Securities Act). The
Shares and the Warrants issued to the purchasers have not been registered under the
Securities Act or any state securities laws. MannKind relied on the exemption from the
registration requirements of the Securities Act set forth in Section 4(2) of the Securities Act and
Rule 506 of Regulation D promulgated under the Securities Act. As described in Item 1.01 of this
current report, MannKind has agreed to file a registration statement for the resale of the Shares
and the shares of common stock underlying the Warrants. Neither this current report on
2.
Form 8-K
nor the exhibits attached hereto is an offer to sell or the solicitation of an offer to buy shares
of common stock or other securities of MannKind.
Item 8.01 Other Events.
The press release, dated August 3, 2005, announcing the Private Placement is attached hereto
as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
|
|
|
99.1
|
|
Securities Purchase Agreement, dated August 2, 2005, by and among MannKind Corporation and
the purchasers listed on Exhibit A thereto. |
|
|
|
99.2
|
|
Press release, dated August 3, 2005, of MannKind Corporation. |
3.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
MANNKIND CORPORATION |
|
|
|
|
|
|
|
|
|
By: |
|
/s/ David Thomson, Ph.D., J.D. |
|
|
|
|
|
|
|
|
|
Name:
|
|
David Thomson, Ph.D., J.D. |
|
|
|
|
Title:
|
|
Corporate Vice President, General Counsel and Secretary |
|
|
|
|
|
|
|
Dated: August 5, 2005 |
|
|
|
|
|
|
4.
INDEX TO EXHIBITS
|
|
|
99.1
|
|
Securities Purchase Agreement, dated August 2, 2005, by and among MannKind
Corporation and the purchasers listed on Exhibit A thereto. |
|
|
|
99.2
|
|
Press release, dated August 3, 2005, of MannKind Corporation. |
5.
exv99w1
Exhibit 99.1
SECURITIES PURCHASE AGREEMENT
This Securities Purchase Agreement (this Agreement), dated as of August 2,
2005, is made by and among MannKind Corporation, a Delaware corporation (the Company),
and the Purchasers listed on Exhibit A hereto, together with their permitted transferees (each, a
Purchaser and collectively, the Purchasers).
Recitals:
A. The Company and the Purchasers are executing and delivering this Agreement in reliance upon
the exemption from securities registration afforded by Section 4(2) of the Securities Act.
B. The Purchasers desire to purchase and the Company desires to sell, upon the terms and
conditions stated in this Agreement, (i) $175,000,131.70 of Common Stock and (ii) warrants to
purchase Common Stock of the Company.
C. The capitalized terms used herein and not otherwise defined have the meanings given them in
Article 7.
AGREEMENT
In consideration of the premises and the mutual covenants contained herein and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company
and the Purchasers (severally and not jointly) hereby agree as follows:
ARTICLE 1
PURCHASE AND SALE OF SECURITIES
1.1 Purchase and Sale of Securities.
(a) Prior to the Closing, the Company shall deliver to a custodian for each Purchaser that has
designated a custodian on such Purchasers signature page hereto, one or more stock certificates
and one or more Warrants (as hereinafter defined) registered in the name of the nominee of such
custodian, evidencing the Securities (as hereinafter defined) to be purchased by such Purchaser
against delivery to the Company by such Purchaser of the purchase price therefor. Such custodian
shall execute a receipt in form reasonably satisfactory to the Company. If, for any reason, the
Closing does not occur within 48 hours of the Companys delivery to the custodian of the stock
certificates and Warrants, such custodian shall immediately return such stock certificates and
Warrants to the Company or an authorized representative thereof.
(b) At the Closing, the Company will issue and sell to each Purchaser, and each Purchaser
will, severally and not jointly, purchase from the Company, the number of shares of Common Stock
(the Shares) and a warrant (the Warrants) to purchase the number of shares of Common Stock set
forth opposite such Purchasers name on Exhibit A hereto (the Shares and Warrants referred to
collectively as the Securities). Each
Purchaser shall receive a
1.
Warrant substantially in the form attached as Exhibit B hereto to purchase the number of
shares of Common Stock equal to 20% of the number of Shares purchased by such Purchaser. Each
Security shall consist of one Share and that portion of the Warrant exercisable for 20% of a share
of Common Stock. The purchase price for each Security shall be $10.215 (the Purchase Price),
consisting of the sum of $10.19 for the Share comprising the Security and $0.025 for the portion of
the Warrant comprising the Security. The Warrants shall bear an initial exercise price per share
equal to $12.228.
1.2 Payment. At the Closing, each Purchaser will pay the aggregate Purchase Price set forth
opposite its name on Exhibit A hereto by wire transfer of immediately available funds in accordance
with wire instructions provided by the Company to the Purchasers prior to the Closing. The Company
will instruct its transfer agent to credit each Purchaser the number of Shares set forth on Exhibit
A (and, upon request, will deliver stock certificates to the Purchasers representing the Shares)
and will deliver Warrants to purchase the Warrant Shares (defined below) against delivery of the
aggregate Purchase Price on the Closing Date.
1.3 Closing Date. The closing of the transaction contemplated by this Agreement will take
place at 10:00 a.m. on August 5, 2005 (the Closing Date) and the closing (the Closing) will be
held at the offices of Cooley Godward llp, 4401 Eastgate Mall, San Diego, CA 92121 or at
such other time and place as shall be agreed upon by the Company and the Purchasers hereunder of a
majority in interest of the Securities.
ARTICLE 2
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
Except as otherwise specifically contemplated by this Agreement, the Company represents and
warrants to, and covenants and agrees with, each Purchaser as follows:
2.1 Organization and Qualification. The Company is duly incorporated, validly existing and in
good standing under the laws of the State of Delaware, with full corporate power and authority to
conduct its business as currently conducted and as disclosed in the SEC Documents. The Company is
duly qualified to do business and is in good standing in every jurisdiction in which the nature of
the business conducted by it or property owned by it makes such qualification necessary, except
where the failure to be so qualified or in good standing, as the case may be, would not reasonably
be expected to have a Material Adverse Effect.
2.2 Subsidiaries. Each Subsidiary of the Company is duly incorporated, validly existing and
in good standing under the laws of the state of its incorporation, with full corporate power and
authority to conduct its business as currently conducted and as disclosed in the SEC Documents.
All of the outstanding shares of capital stock of each Subsidiary of the Company have been duly
authorized and validly issued and are fully paid and non-assessable and are owned, directly or
indirectly, by the Company, free and clear of all liens, claims or other encumbrances, and no
options or warrants to purchase, or any preemptive rights or other rights to subscribe for or to
purchase, or any securities or obligations convertible into or exercisable or exchangeable for, or
any contracts or commitments to issue or sell, shares of capital stock of any Subsidiary or any
such options, rights, convertible, exchangeable or exercisable securities or
2.
obligations are outstanding. Each Subsidiary of the Company is duly qualified to do business
and is in good standing in every jurisdiction in which the nature of the business conducted by it
or property owned by it makes such qualification necessary, except where the failure to be so
qualified or in good standing, as the case may be, would not reasonably be expected to have a
Material Adverse Effect.
2.3 Authorization; Enforcement. The Company has all requisite corporate power and authority
to enter into and to perform its obligations under this Agreement and the Warrant, to consummate
the transactions contemplated hereby and thereby and to issue the Securities and Warrant Shares in
accordance with the terms hereof and thereof. The execution, delivery and performance of this
Agreement and the Warrants by the Company and the consummation by it of the transactions
contemplated hereby and thereby (including the issuance of the Securities and Warrant Shares) have
been duly authorized by the Companys Board of Directors and by a committee of the Board comprised
of directors who are independent of the transactions contemplated by this Agreement and no further
consent or authorization of the Company, its Board of Directors, or its stockholders is required.
This Agreement has been duly executed and delivered by the Company and constitutes a legal, valid
and binding obligation of the Company enforceable against the Company in accordance with its terms
and, at the Closing, each of the Warrants will have been duly executed and delivered by the Company
and will constitute a legal, valid and binding obligation of the Company enforceable against the
Company in accordance with its terms, in each case, except as enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, or moratorium or similar laws affecting
creditors and contracting parties rights generally and except as enforceability may be subject to
general principles of equity and except as rights to indemnity and contribution may be limited by
state or federal securities laws or public policy underlying such laws.
2.4 Capitalization. The authorized capital stock of the Company, as of June 30, 2005,
consisted of 90,000,000 shares of Common Stock, of which 32,833,285 shares were issued and
outstanding, and 10,000,000 shares of Preferred Stock, $0.01 par value per share, none of which
have been designated. All of the issued and outstanding shares of Common Stock have been duly
authorized, validly issued, fully paid, and nonassessable and none of such shares was issued in
violation of preemptive or other similar rights. Options to purchase an aggregate of 4,419,664
shares of Common Stock and warrants to purchase an aggregate of 20,740 shares of Common Stock were
outstanding as of June 30, 2005. Except as disclosed in or contemplated by the SEC Documents, the
Company does not have outstanding any options to purchase, or any preemptive rights or other rights
to subscribe for or to purchase, or any securities or obligations convertible or exchangeable or
exercisable for, or any contracts or commitments to issue or sell, shares of its capital stock or
any such options, rights, convertible, exchangeable or exercisable securities or obligations other
than options granted under the Companys stock option plans and its employee stock purchase plan as
disclosed in the SEC Documents. True, correct and complete copies of the Companys Restated
Certificate of Incorporation (the Certificate of Incorporation) and the Companys Bylaws (the
Bylaws) are each filed as exhibits to the SEC Documents. The capital stock of the Company,
including the Common Stock, conforms to the description thereof contained in the SEC Documents.
2.5 Issuance of Securities. The Shares and all of the shares of Common Stock issuable upon
exercise of the Warrants (the Warrant Shares) have been duly authorized by the
3.
Company and, upon issuance in accordance with the terms of this Agreement (and in case of the
Warrant Shares, the Warrants), will be validly issued, fully paid and non-assessable and will not
be subject to preemptive rights, co-sale rights, rights of first refusal or other similar rights of
stockholders of the Company. Except as disclosed in the SEC Documents, there are no stockholder
agreements, voting agreements or other similar agreements with respect to the Common Stock to which
the Company is a party.
2.6 No Conflicts; Government Consents and Permits.
(a) The execution, delivery and performance of this Agreement and the Warrants by the Company
and the consummation by the Company of the transactions contemplated hereby and thereby (including
the issuance of the Securities and the Warrant Shares) do not and will not (i) conflict with or
result in a violation of any provision of the Certificate of Incorporation or Bylaws or require the
approval of the Companys stockholders or conflict with or result in a violation of any provisions
of the charter or bylaws of any Subsidiary of the Company, or (ii) violate or conflict with, or
result in a breach of any provision of, or constitute a default under, any agreement, indenture, or
instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a
violation of any law, rule, regulation, order, judgment or decree (including United States federal
and state securities laws and regulations and regulations of any self-regulatory organizations to
which the Company or any of its Subsidiaries or their respective securities are subject) applicable
to the Company or any of its Subsidiaries, except in the case of clause (ii) only, for such
conflicts, breaches, defaults, and violations as would not reasonably be expected to have a
Material Adverse Effect.
(b) Neither the Company nor any of its Subsidiaries is required to obtain any consent,
authorization or order of, or make any filing or registration with, any court or governmental
agency or any regulatory or self regulatory agency in order for the Company to execute, deliver or
perform any of its obligations under this Agreement or the Warrants in accordance with the terms
hereof or thereof, or to issue and sell the Securities in accordance with the terms hereof or to
issue the Warrant Shares upon exercise of the Warrants other than such as have been made or
obtained, and except for the registration of the Shares and Warrant Shares under the Securities Act
pursuant to Section 6 hereof, any filings required to be made under federal or state securities
laws (which filings have been or will be made as and when required), and any required filings or
notifications regarding the issuance or listing of additional shares with Nasdaq (which filings and
notifications have been or will be made as and when required).
(c) The Company and its Subsidiaries have all franchises, permits, licenses, and any similar
authority necessary for the conduct of their business as now being conducted by them and as
currently proposed to be conducted as disclosed in the SEC Documents, except for such franchises,
permits, licenses or similar authorities, the lack of which would not reasonably be expected to
have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received any
actual notice of any proceeding relating to revocation or modification of any such franchise,
permit, license, or similar authority except where such revocation or modification would not
reasonably be expected to have a Material Adverse Effect.
2.7 SEC Documents, Financial Statements. The Company has timely filed all reports, schedules,
forms, statements and other documents required to be filed by it with the SEC
4.
since August 2, 2004, pursuant to the reporting requirements of the Exchange Act (all of the
foregoing filed prior to the date hereof and all exhibits included or incorporated by reference
therein and financial statements and schedules thereto and documents (other than exhibits) included
or incorporated by reference therein, being hereinafter referred to herein as the SEC Documents).
Each Purchaser has had access to true and complete copies of the SEC Documents. As of their
respective dates, the SEC Documents complied in all material respects with the requirements of the
Exchange Act or the Securities Act, as the case may be, and the rules and regulations of the SEC
promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time
they were filed with the SEC, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. As of their respective
dates, the Financial Statements and the related notes complied as to form in all material respects
with applicable accounting requirements and the published rules and regulations of the SEC with
respect thereto. The Financial Statements and the related notes have been prepared in accordance
with accounting principles generally accepted in the United States, consistently applied, during
the periods involved (except (i) as may be otherwise indicated in the Financial Statements or the
notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may not
include footnotes, may be condensed or summary statements or may conform to the SECs rules and
instructions for Reports on Form 10-Q) and fairly present in all material respects the consolidated
financial position of the Company as of the dates thereof and the consolidated results of its
operations and cash flows for the periods then ended (subject, in the case of unaudited statements,
to normal and recurring year-end audit adjustments). All agreements that were required to be filed
as exhibits to the SEC Documents under Item 601 of Regulation S-K (collectively, the Material
Agreements) to which the Company or any Subsidiary of the Company is a party, or the property or
assets of the Company or any Subsidiary of the Company are subject, have been filed as exhibits to
the SEC Documents. All Material Agreements are valid and enforceable against the Company or one of
its Subsidiaries, as the case may be, in accordance with their respective terms, except (i) as
enforceability may be limited by applicable bankruptcy, insolvency, reorganization, or moratorium
or similar laws affecting creditors and contracting parties rights generally, and (ii) as
enforceability may be subject to general principles of equity and except as rights to indemnity and
contribution may be limited by state or federal securities laws or public policy underlying such
laws. Neither the Company nor any of its Subsidiaries is in breach of or default under any of the
Material Agreements, and to the Companys knowledge, no other party to a Material Agreement is in
breach of or default under such Material Agreement, except in each case, for such breaches or
defaults as would not reasonably be expected to have a Material Adverse Effect. Neither the
Company nor any of its Subsidiaries has received a notice of termination nor is the Company
otherwise aware of any threats to terminate any of the Material Agreements.
2.8 Sarbanes-Oxley; Disclosure Controls and Procedures. The Company is in compliance in all
material respects with all of the provisions of the Sarbanes-Oxley Act of 2002 that are applicable
to it or any of its Subsidiaries. Except as disclosed in the SEC Documents, the Company has
established and maintains disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) that are effective in all material respects to ensure that material
information relating to the Company, including any of its Subsidiaries, is made known to its chief
executive officer and chief financial officer by others within those entities. The Companys
certifying officers have evaluated the effectiveness of the Companys controls
5.
and procedures as of the end of the period covered by the most recently filed quarterly or
annual periodic report under the Exchange Act (such date, the Evaluation Date). The Company
presented in its most recently filed quarterly or annual periodic report under the Exchange Act the
conclusions of the certifying officers about the effectiveness of the disclosure controls and
procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there
have been no significant changes in the Companys internal controls (as such term is defined in
Item 307(b) of Regulation S-K under the Exchange Act) or, to the Companys knowledge, in other
factors that could significantly affect the Companys internal controls.
2.9 Accounting Controls. Except as disclosed in the SEC Documents, the Company maintains a
system of accounting controls sufficient to provide reasonable assurances that (i) transactions are
executed in accordance with managements general or specific authorization, (ii) transactions are
recorded as necessary to permit preparation of financial statements in conformity with generally
accepted accounting principles as applied in the United States and to maintain accountability for
assets, (iii) access to assets is permitted only in accordance with managements general or
specific authorization, and (iv) the recorded accountability for assets is compared with existing
assets at reasonable intervals and appropriate action is taken with respect to any differences.
The Company is not currently required to comply with (A) the management report on internal control
over financial reporting requirement and the related registered public accounting firm report
requirement contained in Items 308(a) and (b) of Regulation S-K or (B) the provisions of Rule
13a-15(d) or 15d-15(d) promulgated under the Exchange Act requiring an evaluation of changes to
internal control over financial reporting.
2.10 Absence of Litigation. Except as set forth in the SEC Documents, as of the date hereof,
there is no action, suit, proceeding or investigation before or by any court, public board,
government agency, self-regulatory organization or body pending or, to the Companys knowledge,
threatened against the Company or any of its Subsidiaries that if determined adversely to the
Company or any of its Subsidiaries would reasonably be expected to have a Material Adverse Effect
or would reasonably be expected to impair the ability of the Company to perform its obligations
under this Agreement or the Warrants. Neither the Company nor any of its Subsidiaries, nor any
director or officer thereof, is or has been the subject of any action involving a claim of
violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty relating to the Company or any of its Subsidiaries. There has not been, and to the knowledge
of the Company, there is not pending or contemplated, any investigation by the SEC involving the
Company or any of its Subsidiaries or any current or former director or officer of the Company or
any of its Subsidiaries. The Company has not received any stop order or other order suspending the
effectiveness of any registration statement filed by the Company under the Exchange Act or the
Securities Act and, to the Companys knowledge, the SEC has not issued any such order.
2.11 Intellectual Property Rights. To the Companys knowledge, the Company and its
Subsidiaries own or possess, or believes they can obtain on reasonable terms, licenses or
sufficient rights to use all patents, patent applications, patent rights, inventions, know-how,
trade secrets, trademarks, trademark applications, service marks, service names, trade names and
copyrights necessary to enable them to conduct their business as conducted as of the date hereof
(the Intellectual Property). To the Companys knowledge, neither the Company nor any of its
Subsidiaries has infringed the intellectual property rights of third parties and no third party, to
the
6.
Companys knowledge, is infringing the Intellectual Property, in each case, which could
reasonably be expected to result in a Material Adverse Effect. Except as disclosed in the SEC
Documents, there are no material options, licenses or agreements relating to the Intellectual
Property, nor is the Company or any of its Subsidiaries bound by or a party to any material
options, licenses or agreements relating to the patents, patent applications, patent rights,
inventions, know-how, trade secrets, trademarks, trademark applications, service marks, service
names, trade names or copyrights of any other person or entity. There is no material claim or
action or proceeding pending or, to the Companys knowledge, threatened that challenges the right
of the Company or any of its Subsidiaries with respect to any Intellectual Property.
2.12 Placement Agents. The Company has taken no action that would give rise to any claim by
any person for brokerage commissions, placement agents fees or similar payments relating to this
Agreement or the transactions contemplated hereby, except for dealings with the Placement Agents,
whose commissions and fees will be paid by the Company. For purposes of clarity, the Company
hereby represents and warrants that the Placement Agents have not participated in the placement of
any Securities that are to be purchased by any director or officer of the Company (the Company
Representatives) and that no commissions or fees will be paid to the Placement Agents in
connection with any Securities sold to Company Representatives.
2.13 Investment Company. The Company is not and, after giving effect to the offering and sale
of the Securities and the receipt of the proceeds therefrom, will not be an investment company as
such term is defined in the Investment Company Act of 1940, as amended (the Investment Company
Act). The Company shall conduct its business in a manner so that it will not become subject to
the Investment Company Act.
2.14 No Material Adverse Change. Since December 31, 2004, except as described or referred to
in the SEC Documents and except for cash expenditures in the ordinary course of business, there has
not been any change in the assets, business, properties, financial condition or results of
operations of the Company that would reasonably be expected to have a Material Adverse Effect.
Since December 31, 2004, (i) there has not been any dividend or distribution of any kind declared,
set aside for payment, paid or made by the Company on any class of capital stock, (ii) neither the
Company nor any of its Subsidiaries has sustained any material loss or interference with its
business from fire, explosion, flood or other calamity, whether or not covered by insurance, or
from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or
governmental or regulatory authority, (iii) neither the Company nor any of its Subsidiaries has
incurred any liabilities except in the ordinary course of business, (iv) the Company has not
altered its method of accounting, and (v) the Company has not issued any equity securities to any
officer, director, or Affiliate of the Company, except pursuant to the transaction contemplated by
this Agreement or pursuant to existing Company stock option or purchase plans.
2.15 Nasdaq National Market. The Common Stock is listed on Nasdaq, and, to the Companys
knowledge, there are no proceedings to revoke or suspend such listing or the listing of the Shares
and the Warrant Shares. The Company is in compliance with the requirements of Nasdaq for continued
listing of the Common Stock thereon and any other Nasdaq listing and maintenance requirements. At
the Closing, the Shares will have been duly listed on Nasdaq and the Warrant Shares will have been
approved for listing on Nasdaq.
7.
2.16 Acknowledgment Regarding Purchasers Purchase of Securities. The Company acknowledges and
agrees that each of the Purchasers is acting solely in the capacity of an arms length purchaser
with respect to this Agreement and the transactions contemplated hereby. The Company further
acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in
any similar capacity with respect to the Company) with respect to this Agreement and the
transactions contemplated hereby and any advice given by any Purchaser or any of their respective
representatives or agents to the Company in connection with this Agreement and the transactions
contemplated hereby is merely incidental to such Purchasers purchase of the Securities. The
Company further represents to each Purchaser that the Companys decision to enter into this
Agreement has been based on the independent evaluation of the transactions contemplated hereby by
the Company and its representatives.
2.17 Accountants. Deloitte & Touche LLP, who have expressed their opinion with respect to the
audited financial statements and schedules to be incorporated by reference in or included as a part
of the Registration Statement prior to the filing of the Registration Statement, are independent
accountants as required by the Securities Act.
2.18 Insurance. The Company and each of its Subsidiaries is insured by insurers of recognized
financial responsibility against such losses and risks and in such amounts as the Company believes
are prudent and customary for a company (i) in the businesses and location in which the Company or
such Subsidiary, as the case may be, is engaged, (ii) with the resources of the Company, and (iii)
at a similar stage of development as the Company. Neither the Company nor any of its Subsidiaries
have received any written notice that it will not be able to renew its existing insurance coverage
as and when such coverage expires. The Company believes it will be able to obtain similar coverage
at reasonable cost from similar insurers as may be necessary for the Company and each of its
Subsidiaries to continue its business.
2.19 Foreign Corrupt Practices. Since December 31, 2004, neither the Company nor any of its
Subsidiaries, nor to the Companys knowledge, any director, officer, agent, employee or other
person acting on behalf of the Company or any of its Subsidiaries has, in the course of its actions
for, or on behalf of, the Company or any of its Subsidiaries (i) used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful expenses relating to political
activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government
official or employee from corporate funds; (iii) violated or is in violation of in any material
respect any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made
any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any
foreign or domestic government official or employee.
2.20 Private Placement. Neither the Company nor its Subsidiary or any affiliates, nor any
person acting on its or their behalf, has, directly or indirectly, made any offers or sales of any
security or solicited any offers to buy any security, under any circumstances that would require
registration of the Securities under the Securities Act.
2.21 No Registration Rights. No person has the right, which right has not been waived, to (i)
prohibit the Company from filing the Registration Statement, or (ii) require the Company to
register any securities for sale under the Securities Act by reason of the filing of the
Registration Statement or (iii) register any securities (other than Securities and Warrant Shares)
8.
pursuant to the Registration Statement. The granting and performance of the registration
rights under this Agreement will not violate or conflict with, or result in a breach of any
provision of, or constitute a default under, any instrument or agreement to which the Company or
any of its Subsidiaries is a party or by which any of them is bound.
2.22 Taxes. The Company and each of its Subsidiaries has filed (or has obtained an extension
of time within which to file) all necessary federal, state and foreign income and franchise tax
returns and has paid all taxes shown as due on such tax returns, except where the failure to so
file or the failure to so pay would not reasonably be expected to have a Material Adverse Effect.
The Company is not aware of any tax deficiency that has been or might be asserted against it that
would have a Material Adverse Effect.
2.23 Real and Personal Property. The Company and each of its Subsidiaries has good and
marketable title to, or has valid rights to lease or otherwise use, all items of real and personal
property that are material to its business free and clear of all liens, encumbrances, claims and
defects and imperfections of title except those that (i) do not materially interfere with the use
of such property or (ii) would not reasonably be expected to have a Material Adverse Effect.
2.24 Application of Takeover Protections. The execution and delivery of this Agreement and the
Warrant and the consummation of the transactions contemplated hereby and thereby will not impose
any restriction on any Purchaser, or create in any party (including any current stockholder of the
Company) any rights, under any share acquisition, business combination, poison pill (including any
distribution under a rights agreement), or other similar anti-takeover provisions under the
Companys charter documents or the laws of its state of incorporation.
2.25 No Manipulation of Stock. The Company has not taken, nor will it take, directly or
indirectly, any action designed to stabilize or manipulate of the price of the Common Stock or any
security of the Company to facilitate the sale or resale of any of the Shares.
2.26 Related Party Transactions. Except with respect to the transactions contemplated hereby,
all transactions that have occurred between or among the Company or any of its Subsidiaries, on the
one hand, and any of their respective officers or directors, or any affiliate or affiliates of any
such officer or director, on the other hand, prior to the date hereof have been disclosed in the
SEC Documents to the extent required to be disclosed by the Exchange Act and the rules and
regulations promulgated thereunder.
2.27 Trials. The preclinical tests and clinical trials that are described in, or the results
of which are referred to in, the SEC Documents were and, if still pending, are being conducted in
accordance with protocols, procedures, and controls pursuant to accepted professional scientific
standards filed with the appropriate regulatory authorities for each such test or trial, as the
case may be. The description of the results of such tests and trials contained in the SEC
Documents are accurate in all material respects, and the Company has no knowledge of any other
studies or tests the results of which call into question the results described or referred to in
the SEC Documents. The Company has not received any notices or other correspondence from the Food
and Drug Administration of the U.S. Department of Health and Human Services or any
9.
committee thereof or from any other governmental agency requiring the termination, suspension
or modification of any clinical trials currently conducted by or on behalf of the Company or in
which the Company has participated that are described or referred to in the SEC Documents.
2.28 Compliance. Neither the Company nor any Subsidiary (i) is in default under or in
violation of (and to the knowledge of the Company no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any
Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in
default under or that it is in violation of, any indenture, loan or credit agreement or any other
agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any order of
any court, arbitrator or governmental body, or (iii) is or has been in violation of any statute,
rule or regulation of any governmental authority, including without limitation all foreign,
federal, state and local laws applicable to its business, except in each case as would not
reasonably be expected to have a Material Adverse Effect.
ARTICLE 3
PURCHASERS REPRESENTATIONS AND WARRANTIES
Each Purchaser represents and warrants to, and covenants and agrees with, the Company,
severally and not jointly, with respect to itself and its purchase hereunder, as follows:
3.1 Investment Purpose. Such Purchaser is purchasing the Securities for its own account and
not with a present view toward the public sale or distribution thereof and has no intention of
selling or distributing any of such Securities or any arrangement or understanding with any other
persons regarding the sale or distribution of such Securities except in accordance with the
provisions of Article 6 and except as would not result in a violation of the Securities Act. Such
Purchaser will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of
(or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the
Securities except in accordance with the provisions of Article 6 or pursuant to and in accordance
with the Securities Act.
3.2 Questionnaires. The information required by the Stock Certificate and Warrant
Questionnaire and the information required by the Registration Statement Questionnaire submitted by
such Purchaser to the Company in connection with its purchase of the Securities was accurate and
correct when delivered and is accurate and correct as of the date hereof.
3.3 Reliance on Exemptions. Such Purchaser understands that the Securities are being offered
and sold to it in reliance upon specific exemptions from the registration requirements of United
States federal and state securities laws and that the Company is relying upon the truth and
accuracy of, and such Purchasers compliance with, the representations, warranties, agreements,
acknowledgments and understandings of such Purchaser set forth herein in order to determine the
availability of such exemptions and the eligibility of such Purchaser to acquire the Securities.
10.
3.4 Information. Such Purchaser has been furnished with all relevant materials relating to
the business, finances and operations of the Company necessary to make an investment decision, and
materials relating to the offer and sale of the Securities, that have been requested by such
Purchaser, including, without limitation, the Companys SEC Documents, and such Purchaser has had
the opportunity to review the SEC Documents. Such Purchaser has been afforded the opportunity to
ask questions, and to receive answers from, officers and employees of the Company concerning the
Company and the terms and conditions of this offering and to obtain additional information about
the Company and the Securities. Neither such inquiries nor any other investigation conducted by or
on behalf of such Purchaser or its representatives or counsel shall modify, amend or affect such
Purchasers right to rely on the truth, accuracy and completeness of the SEC Documents or any other
materials furnished to such Purchaser by the Company in connection herewith and the Companys
representations and warranties contained in this Agreement.
3.5 Acknowledgement of Risk.
(a) Such Purchaser acknowledges and understands that its investment in the Securities involves
a significant degree of risk, including, without limitation, (i) the Company remains a development
stage business with limited operating history and requires substantial funds in addition to the
proceeds from the sale of the Securities; (ii) an investment in the Company is speculative, and
only purchasers who can afford the loss of their entire investment should consider investing in the
Company and the Securities; (iii) such Purchaser may not be able to liquidate its investment; (iv)
transferability of the Securities is extremely limited; (v) in the event of a disposition of the
Securities, such Purchaser could sustain the loss of its entire investment; and (vi) the Company
has not paid any dividends on its Common Stock since inception and does not anticipate the payment
of dividends in the foreseeable future. Such risks, and others applicable to the Company, are more
fully set forth in the SEC Documents;
(b) Such Purchaser is able to bear the economic risk of holding the Securities for an
indefinite period, and has knowledge and experience in financial and business matters such that it
is capable of evaluating the risks of the investment in the Securities; and
(c) Such Purchaser has, in connection with such Purchasers decision to purchase Securities,
not relied upon any representations or other information (whether oral or written) other than as
set forth in the representations and warranties of the Company contained herein and in the SEC
Documents, and such Purchaser has, with respect to all matters relating to this Agreement and the
offer and sale of the Securities, relied solely upon the advice of such Purchasers own counsel and
has not relied upon or consulted any counsel to the Placement Agents or counsel to the Company and
has not relied upon any Placement Agent.
3.6 Governmental Review. Such Purchaser understands that no United States federal or state
agency or any other government or governmental agency has passed upon or made any recommendation or
endorsement of the Securities or an investment therein.
11.
3.7 Transfer or Resale. Such Purchaser understands that:
(a) the Securities have not been and are not being registered under the Securities Act (other
than as contemplated in Article 6) or any applicable state securities laws and, consequently, such
Purchaser may have to bear the risk of owning the Securities for an indefinite period of time
because the Securities may not be transferred unless (i) the resale of the Securities is registered
pursuant to an effective registration statement under the Securities Act, as contemplated in
Article 6; or (ii) such Purchaser has delivered to the Company an opinion of counsel (in form,
substance and scope customary for opinions of counsel in comparable transactions) to the effect
that the Securities to be sold or transferred may be sold or transferred pursuant to an exemption
from or in a transaction not subject to such registration; or (iii) the Securities are sold or
transferred pursuant to Rule 144;
(b) any sale of the Securities made in reliance on Rule 144 may be made only in accordance
with the terms of Rule 144 and, if Rule 144 is not applicable, any resale of the Securities under
circumstances in which the seller (or the person through whom the sale is made) may be deemed to be
an underwriter (as that term is defined in the Securities Act) may require compliance with some
other exemption under the Securities Act or the rules and regulations of the SEC thereunder; and
(c) except as set forth in Article 6, neither the Company nor any other person is under any
obligation to register the resale of the Shares or the Warrant Shares under the Securities Act or
any state securities laws or to comply with the terms and conditions of any exemption thereunder.
3.8 Legends.
(a) Such Purchaser understands the certificates representing the Securities and the Warrant
Shares will bear a restrictive legend in substantially the following form (and a stop-transfer
order may be placed against transfer of the certificates for such Securities and Warrant Shares):
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES
MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF
AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS, OR UNLESS
OFFERED, SOLD, PLEDGED, HYPOTHECATED OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM OR IN A
TRANSACTION NOT SUBJECT TO THE REGISTRATION REQUIREMENTS OF THOSE LAWS. THE COMPANY SHALL BE
ENTITLED TO REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED TO THE EXTENT THAT SUCH OPINION IS REQUIRED PURSUANT TO THAT CERTAIN
SECURITIES PURCHASE AGREEMENT UNDER WHICH THE SECURITIES WERE ISSUED.
12.
(b) Such Purchaser may request that the Company remove, and the Company agrees to authorize
the removal of any legend from the Securities and Warrant Shares, (i) following any sale of the
Securities or Warrant Shares pursuant to an effective Registration Statement or Rule 144, or (ii)
if such Securities or Warrant Shares are eligible for sale under Rule 144(k). Following the time a
legend is no longer required for the Securities or Warrant Shares hereunder, the Company will, no
later than three Business Days following the delivery by such Purchaser to the Company or the
Companys transfer agent of a legended certificate representing such securities, deliver or cause
to be delivered to such Purchaser a certificate representing such securities that is free from all
restrictive and other legends and is not subject to any stop transfer or other similar
restrictions.
3.9 Authorization; Enforcement. Such Purchaser has the requisite power and authority to enter
into this Agreement and to consummate the transactions contemplated hereby. The Purchaser has
taken all necessary action to authorize the execution, delivery and performance of this Agreement
by such Purchaser. Upon the execution and delivery of this Agreement, this Agreement shall
constitute a valid and binding obligation of such Purchaser enforceable in accordance with its
terms, except as enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors and contracting parties rights
generally and except as enforceability may be subject to general principles of equity and except as
rights to indemnity and contribution may be limited by state or federal securities laws or public
policy underlying such laws.
3.10 Residency. Such Purchaser is a resident of the jurisdiction set forth immediately below
such Purchasers name on the signature pages hereto.
3.11 No Trades. Between the time such Purchaser learned about the Offering and the public
announcement of the Offering, such Purchaser has not engaged in any purchase, sale or other
transaction, including any short sales, with respect to the Common Stock, nor has such Purchaser,
directly or indirectly, caused any Person to engage in any purchase, sale or other transaction,
including any short sales, with respect to the Common Stock.
3.12 Acknowledgements Regarding Placement Agent. Such Purchaser acknowledges that the
Placement Agents are acting as the exclusive placement agents for the Securities being offered
hereby (other than the Securities being offered or sold to the Company Representatives) and will be
compensated solely by the Company for acting in such capacity. Such Purchaser represents that (i)
if such Purchaser is not a Company Representative, such Purchaser was contacted regarding the sale
of the Securities by the Placement Agent (or an authorized agent or representative thereof) or, if
such Purchaser is a Company Representative, such Purchaser was contacted regarding the sale of the
Securities by the Company (or an authorized officer or employee thereof) and (ii) no Securities
were offered or sold to it by means of any form of general solicitation or general advertising.
3.13 Expenses. Such Purchaser is liable for and will pay its own expenses incurred in
connection with the negotiation, preparation, execution and delivery of this Agreement and the
Warrants, including, without limitation, attorneys and consultants fees and expenses.
13.
ARTICLE 4
COVENANTS
Except as specifically contemplated by this Agreement, the Company represents and warrants to,
and covenants and agrees with, each Purchaser as follows:
4.1 Reporting Status. The Companys Common Stock is registered under Section 12 of the
Exchange Act. Until the earlier of (i) the second anniversary of the Closing Date and (ii) the
date all Shares and Warrant Shares may be sold under Rule 144(k), the Company will timely file all
documents with the SEC and will take all other actions as are necessary to insure that the
exemption from registration under Rule 144 is available to Holders of Shares and Warrant Shares,
and the Company will not terminate its status as an issuer required to file reports under the
Exchange Act even if the Exchange Act or the rules and regulations thereunder would permit such
termination.
4.2 Expenses. The Company is liable for and will pay its own expenses incurred in connection
with the negotiation, preparation, execution and delivery of this Agreement and the Warrants,
including, without limitation, attorneys and consultants fees and expenses.
4.3 Financial Information. The financial statements and related notes of the Company to be
included in any documents filed with the SEC will be prepared in accordance with accounting
principles generally accepted in the United States, consistently applied (except (i) as may be
otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of
unaudited interim statements, to the extent they may not include footnotes, may be condensed or
summary statements or may conform to the SECs rules and instructions for Reports on Form 10-Q),
and will fairly present in all material respects the consolidated financial position of the Company
and consolidated results of its operations and cash flows as of, and for the periods covered by,
such financial statements (subject, in the case of unaudited statements, to normal and recurring
year-end audit adjustments).
4.4 Securities Laws Disclosure; Publicity. On or before 9:30 a.m., New York local time, on
August 3, 2005 the Company shall issue a press release announcing the signing of this Agreement and
describing the terms of the transactions contemplated by this Agreement. On or before August 9,
2005, the Company shall file a Current Report on Form 8-K with the SEC describing the terms of the
transactions contemplated by this Agreement and including as an exhibit to such Current Report on
Form 8-K this Agreement, in the form required by the Exchange Act. The Company shall not otherwise
publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing
with the Commission (other than the Registration Statement and in filings made in accordance with
periodic filing requirements under the Exchange Act) or any regulatory agency, without the prior
written consent of such Purchaser, except to the extent such disclosure is required by law or
regulations, in which case the Company shall provide the Purchasers with prior written notice of
such disclosure.
4.5 Reservation of Common Stock. The Company will reserve and keep available at all times
during which the Warrants remain exercisable, free of preemptive rights, a sufficient
14.
number of shares of Common Stock for the purpose of enabling the Company to issue Warrant
Shares pursuant to this Agreement and the Warrants.
ARTICLE 5
CONDITIONS TO CLOSING
5.1 Conditions to Obligations of the Company. The Companys obligation to complete the sale
of the Securities and deliver stock certificate(s) and Warrants to each Purchaser is subject to the
fulfillment or waiver as of the Closing Date of the following conditions:
(a) Receipt of Funds. The Company shall have received immediately available funds in the full
amount of the purchase price for the Securities being purchased hereunder as set forth opposite
such Purchasers name on Exhibit A hereto.
(b) Representations and Warranties. The representations and warranties made by each Purchaser
in Article 3 shall be true and correct as of the Closing Date.
(c) Covenants. All covenants, agreements and conditions contained in this Agreement to be
performed by the Purchasers on or prior to the Closing Date shall have been performed or complied
with in all material respects.
(d) Blue Sky. The Company shall have obtained all necessary blue sky law permits and
qualifications, or secured exemptions therefrom, required by any state for the offer and sale of
the Securities.
(e) Nasdaq Qualification. The Shares and the Warrant Shares to be issued shall be duly
authorized for listing by Nasdaq, subject to official notice of issuance.
(f) Absence of Litigation. No proceeding challenging this Agreement or the transactions
contemplated hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, shall
have been instituted or be pending before any court, arbitrator, governmental body, agency or
official.
(g) No Governmental Prohibition. The sale of the Securities by the Company shall not be
prohibited by any law or governmental order or regulation.
5.2 Conditions to Purchasers Obligations at the Closing. Each Purchasers obligation to
complete the purchase of the Securities set forth opposite such Purchasers name on Exhibit A
hereto is subject to the fulfillment or waiver as of the Closing Date of the following conditions:
(a) Representations and Warranties. The representations and warranties made by the Company in
Article 2 shall be true and correct in all material respects as of the Closing Date.
15.
(b) Covenants. All covenants, agreements and conditions contained in this Agreement to be
performed by the Company on or prior to the Closing Date shall have been performed or complied with
in all material respects.
(c) Blue Sky. The Company shall have obtained all necessary blue sky law permits and
qualifications, or secured exemptions therefrom, required by any state or foreign or other
jurisdiction for the offer and sale of the Shares.
(d) Legal Opinion. The Company shall have delivered to such Purchaser an opinion, dated as of
the Closing Date, from Cooley Godward llp, counsel to the Company, in form and substance
reasonably satisfactory to the Purchaser.
(e) Transfer Agent Instructions. The Company shall have delivered to its transfer agent
irrevocable instructions to issue to such Purchaser or in such nominee name(s) as designated by
such Purchaser in writing such number of Shares set forth opposite such Purchasers name on Exhibit
A hereto or, if requested by the Purchaser, one or more certificates representing such shares, and
a Warrant to purchase the number of Warrant Shares set forth opposite such Purchasers name on
Exhibit A.
(f) Nasdaq Qualification. The Shares and the Warrant Shares shall be duly authorized for
listing by Nasdaq, subject to official notice of issuance.
(g) Absence of Litigation. No proceeding challenging this Agreement or the transactions
contemplated hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, shall
have been instituted or be pending before any court, arbitrator, governmental body, agency or
official.
(h) No Governmental Prohibition. The sale of the Securities by the Company and the purchase
of Securities by such Purchaser shall not be prohibited by any law or governmental order or
regulation.
(i) Company Representative Purchasers. Directors, officers, and Affiliates of the Company
shall have entered into binding Agreements with the Company to purchase $87,500,000 in Securities.
(j) Minimum Purchase. The Purchasers shall purchase at least $150,000,000 in Securities at
the Closing.
ARTICLE 6
REGISTRATION RIGHTS
6.1 As soon as reasonably practicable, but in no event later than 30 days after the Closing
Date (the Filing Date), the Company shall file a registration statement covering the resale of
the Registrable Securities on a registration statement (the Registration Statement) with the SEC.
As promptly as possible after the filing of the Registration Statement, but in any event prior to
the Effectiveness Date (defined below), the Company will use its best efforts to cause the
Registration Statement to be declared effective by the SEC and will otherwise effect all
16.
such registrations, obtain all such qualifications and comply with all such laws, rules and
regulations as may be necessary in order to permit the sale, transfer and other disposition of the
Registrable Securities by the Holders thereof pursuant to the Registration Statement (including,
without limitation, the execution of any required undertaking to file post-effective amendments,
appropriate qualifications or exemptions under applicable blue sky or other state securities laws
and appropriate compliance with applicable securities laws, requirements or regulations). As used
herein, Effectiveness Date means the date which is (i) 60 days after the Closing Date if the
Registration Statement is not reviewed by the SEC, or (ii) 120 days after the Closing Date, if the
Registration Statement is reviewed by the SEC.
6.2 All Registration Expenses incurred in connection with any registration, qualification,
exemption or compliance pursuant to Section 6.1 shall be borne by the Company. All Selling
Expenses relating to the sale of Registrable Securities registered by or on behalf of any Holder
shall be borne by such Holder.
6.3 The Company further agrees that, in the event that the Registration Statement (i) has not
been filed with the SEC within 30 days after the Closing Date, (ii) has not been declared effective
by the SEC by the Effectiveness Date, or (iii) after the Registration Statement is declared
effective by the SEC, the use of the Registration Statement or the related prospectus is suspended
by the Company, or the Registration Statement ceases to remain continuously effective as to all
Registrable Securities for which it is required to be effective, or the Registration Statement or
the related prospectus cease to be useable in connection with resales of Registrable Securities for
which it is required to be effective, other than, in each case referred to in this clause (iii),
within the time period(s) permitted by Section 6.7(b) (each such event referred to in clauses (i),
(ii) and (iii), a Registration Default), then, for any thirty-day period (a Penalty Period)
during which the Registration Default remains uncured, the Company shall pay to each Holder an
amount in cash equal to 1% of such Holders aggregate deemed purchase price of his or her
Registrable Securities for each Penalty Period during which the Registration Default remains
uncured (for purposes of clarity, it is hereby understood and agreed that, solely for the purpose
of this Section 6.3, the deemed purchase price for each Share is $10.19 and the purchase price of
each Warrant Share shall be deemed to be equal to $0.025, provided that the dollar amounts set
forth in this parenthetical clause shall be appropriately adjusted in the event of any adjustment,
pursuant to the terms of the Warrants, in the exercise price of the Warrants or the number of
shares issuable upon exercise of the Warrants); provided, however, that if a Holder fails to
provide the Company with any information that is required to be provided in the Registration
Statement with respect to such Holder as set forth herein, then the commencement of the Penalty
Period described above shall be extended until two Business Days following the date of receipt by
the Company of such required information; and provided, further, that in no event shall the Company
be required hereunder to pay to any Holder pursuant to this Agreement an aggregate amount that
exceeds 21% of the aggregate deemed purchase price for such Holders Securities; and provided
further that the amount payable to any Holder hereunder for any partial Penalty Period shall be
pro-rated for the number of actual days during such Penalty Period during which a Registration
Default remains uncured. The Company shall deliver said cash payment to each Holder entitled
thereto by the fifth Business Day after the end of such Penalty Period (or, in the case of a
partial Penalty Period, by the fifth Business Day after the applicable Registration Default shall
have been cured or shall have ceased to exit). If the Company fails to pay said cash payment to a
Holder entitled thereto by the applicable date specified in the
17.
immediately preceding sentence, the Company will pay interest thereon at a rate of 12% per
annum (or such lesser maximum amount that is permitted to be paid by applicable law) to such
Holder, accruing daily from the date such liquidated damages are due until such amounts, plus all
such interest thereon, are paid in full.
6.4 In the case of the registration, qualification, exemption or compliance effected by the
Company pursuant to this Agreement, the Company shall, upon reasonable request, inform each Holder
as to the status of such registration, qualification, exemption and compliance. At its expense the
Company shall:
(a) except for such times as the Company is permitted hereunder to suspend the use of the
prospectus forming part of the Registration Statement, use all commercially reasonable efforts to
keep such registration, and any qualification, exemption or compliance under state securities laws
which the Company determines to obtain or which the Company obtains at the request of a Holder
pursuant to Section 6.4(g), continuously effective with respect to a Holder, and to keep such
Registration Statement and the related prospectus free of any material misstatements or omissions,
until the earlier of the following: (i) the second anniversary of the Closing Date or (ii) the
date all Shares and Warrant Shares held by such Holder may be sold under Rule 144 during any 90 day
period. The period of time during which the Company is required hereunder to keep the Registration
Statement effective is referred to herein as the Registration Period.
(b) advise the Holders:
(i) within two Business Days when the Registration Statement or any amendment thereto has been
filed with the SEC and when the Registration Statement or any post-effective amendment thereto has
become effective;
(ii) as promptly as practicable of any request by the SEC for amendments or supplements to the
Registration Statement or the prospectus included therein or for additional information;
(iii) as promptly as practicable of the issuance by the SEC of any stop order suspending the
effectiveness of the Registration Statement or the initiation of any proceedings for such purpose;
(iv) as promptly as practicable of the receipt by the Company of any notification with respect
to the suspension of the qualification of the Registrable Securities included therein for sale in
any jurisdiction or the initiation or threatening of any proceeding for such purpose; and
(v) as promptly as practicable of the occurrence of any event or the existence of any
condition that requires the making of any changes in the Registration Statement or the prospectus
so that, as of such date, the statements therein are not misleading and do not omit to state a
material fact required to be stated therein or necessary to make the statements therein (in the
case of the prospectus, in the light of the circumstances under which they were made) not
misleading;
18.
(c) use its commercially reasonable efforts to obtain the withdrawal of any order suspending
the effectiveness of any Registration Statement as soon as reasonably practicable;
(d) if a Holder so requests in writing, promptly furnish to each such Holder, without charge,
at least one copy of such Registration Statement and any post-effective amendment thereto,
including financial statements and schedules, and, if explicitly requested, all exhibits in the
form filed with the SEC;
(e) during the Registration Period, promptly deliver to each such Holder, without charge, five
copies of the prospectus included in such Registration Statement and any amendment or supplement
thereto as such number of additional copies thereof as such Holder may reasonably request in
writing; and the Company consents to the use, consistent with the provisions hereof, of the
prospectus or any amendment or supplement thereto by each of the Holders in connection with the
offering and sale of the Registrable Securities covered by the prospectus or any amendment or
supplement thereto;
(f) during the Registration Period, if a Holder so requests in writing, deliver to each
Holder, without charge, (i) one copy of the following documents, other than those documents
available via EDGAR (and excluding, in each case, exhibits thereto): (A) its annual report to its
stockholders, if any (which annual report shall contain financial statements audited in accordance
with generally accepted accounting principles in the United States of America by a firm of
certified public accountants of recognized standing), (B) if not included in substance in its
annual report to stockholders, its annual report on Form 10-K (or similar form), (C) its definitive
proxy statement with respect to its annual meeting of stockholders, (D) each of its quarterly
reports to its stockholders, and, if not included in substance in its quarterly reports to
stockholders, its quarterly report on Form 10-Q (or similar form), and (E) a copy of the full
Registration Statement; and (ii) if explicitly requested, any exhibits filed with respect to the
foregoing;
(g) promptly take such actions as may be necessary to register or qualify or obtain an
exemption for offer and sale under the securities or blue sky laws of such United States
jurisdictions as any Holders reasonably request in writing, provided that the Company shall not for
any such purpose be required to qualify generally to transact business as a foreign corporation in
any jurisdiction where it is not so qualified or to consent to general service of process in any
such jurisdiction, and do any and all other acts or things reasonably necessary or advisable to
enable the offer and sale in such jurisdictions of the Registrable Securities covered by such
Registration Statement;
(h) upon the occurrence of any event contemplated by Section 6.4(b)(v) above, except for such
times as the Company is permitted hereunder to suspend the use of the prospectus forming part of
the Registration Statement and has suspended such use, the Company shall use all commercially
reasonable efforts to as soon as reasonably practicable prepare a post-effective amendment to the
Registration Statement or a supplement to the related prospectus, or file any other required
document so that, as thereafter delivered to purchasers of the Registrable Securities, the
prospectus will not include any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the
19.
statements therein, in the light of the circumstances under which they were made, not
misleading;
(i) otherwise use all commercially reasonable efforts to comply in all material respects with
all applicable rules and regulations of the SEC which could affect the sale of the Registrable
Securities;
(j) use all commercially reasonable efforts to cause all Registrable Securities to be listed
on each securities exchange or market, if any, on which equity securities issued by the Company
have been listed;
(k) use all commercially reasonable efforts to take all other steps necessary to effect the
registration of the Registrable Securities contemplated hereby and to enable the Holders to sell
Registrable Securities under Rule 144;
(l) provide to each Holder and its representatives, if requested, the opportunity to conduct a
reasonable inquiry of the Companys financial and other records during normal business hours and
make available its officers, directors and employees for questions regarding information which such
Holder may reasonably request in order to fulfill any due diligence obligation on its part; and
(m) permit a single counsel for the Holder to review the Registration Statement and all
amendments and supplements thereto, within two Business Days prior to the filing thereof with the
Commission, to give reasonable consideration to any comments from such counsel and, without
limitation to the foregoing, to make such changes to the plan of distribution section of such
Registration Statement or any amendments or supplements thereto as may be reasonably requested by
any Holder;
provided that, in the case of clauses (l) and (m) above, the Company shall not be required (A) to
delay the filing of the Registration Statement or any amendment or supplement thereto as a result
of any ongoing diligence inquiry by or on behalf of a Holder, or (B) to provide, and shall not
provide, any Holder or its representatives with material, non-public information unless such Holder
agrees to receive such information and enters into a written confidentiality agreement with the
Company in a form reasonably acceptable to the Company.
6.5 The Company shall not be required to make any payment to any Holder otherwise required by
Section 6.3 hereof allocable to any day on which a Registration Default exists or existed solely as
a result of (i) any request by such Holder to incorporate any comment in any Registration Statement
or amendment or supplement thereto or (ii) any unreasonable action by such Holder to restrain,
enjoin or otherwise delay any registration pursuant to Section 6.1 hereof.
6.6 (a) To the extent permitted by law, the Company shall indemnify each Holder and each
person controlling such Holder within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act, against all claims, losses, damages and liabilities (or action in respect
thereof), including any of the foregoing incurred in settlement of any litigation, commenced or
threatened (subject to Section 6.6(c) below), arising out of or based on any untrue statement (or
alleged untrue statement) of a material fact contained in the Registration Statement, any
prospectus, any amendment or supplement to any such Registration Statement or prospectus,
20.
or any other document incident to any such registration, qualification or compliance or
arising out of or based on any omission (or alleged omission) to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, in light
of the circumstances in which they were made, or arising out of or based on any violation by the
Company of any rule or regulation promulgated by the SEC applicable to the Company and relating to
any action or inaction required of the Company in connection with any such registration,
qualification or compliance, and will reimburse each Holder and each person controlling such
Holder, for legal and other out-of-pocket expenses reasonably incurred in connection with
investigating or defending any such claim, loss, damage, liability or action as incurred; provided
that the Company will not be liable in any such case to the extent that any untrue statement or
omission or allegation thereof is made in reliance upon and in conformity with written information
furnished to the Company by or on behalf of such Holder for use in preparation of such Registration
Statement, prospectus, amendment or supplement; provided further that the foregoing indemnity
agreement is subject to the condition that, insofar as it relates to any such untrue statement or
alleged untrue statement or omission or alleged omission made in the preliminary prospectus but
eliminated or remedied in the prospectus on file with the SEC at the time the Registration
Statement becomes effective or in the prospectus filed with the SEC pursuant to Rule 424(b) (the
Final Prospectus), such indemnity shall not inure to the benefit of any such Holder in connection
with the sale of Registrable Securities to any purchaser by such Holder, or any such controlling
person of such Holder, if a copy of the Final Prospectus was furnished to such Holder by the
Company for delivery to the purchaser of such Registrable Securities but was not furnished to the
purchaser of such Registrable Securities at or prior to the time such furnishing is required by the
Securities Act and the Final Prospectus would have cured the defect giving rise to such loss,
liability, claim or damage.
(b) Each Holder will severally, and not jointly, indemnify the Company, each of its directors,
each of its officers who signed the Registration Statement, and each person who controls the
Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act,
against all claims, losses, damages and liabilities (or actions in respect thereof), including any
of the foregoing incurred in settlement of any litigation, commenced or threatened (subject to
Section 6.6(c) below), arising out of or based on any untrue statement (or alleged untrue
statement) of a material fact contained in the Registration Statement, any prospectus, or any
amendment or supplement to any such Registration Statement or prospectus, or arising out of or
based on any omission (or alleged omission) to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, in light of the circumstances
in which they were made, and will reimburse the Company, such directors and officers, and each
person controlling the Company for legal and any other expenses reasonably incurred in connection
with investigating or defending any such claim, loss, damage, liability or action as incurred, in
each case to the extent, but only to the extent, that such untrue statement or omission or
allegation thereof is made in reliance upon and in conformity with written information furnished to
the Company by or on behalf of the Holder for use in preparation of the Registration Statement or
such prospectus, amendment or supplement;
provided that the indemnity shall not apply to the extent
that such claim, loss, damage or liability results from the fact that a current copy of the
prospectus was not made available to the person or entity asserting the loss, liability, claim or
damage at or prior to the time such furnishing is required by the Securities Act and the Final
Prospectus would have cured the defect giving rise to such loss, claim, damage or liability.
Notwithstanding the foregoing, a Holders aggregate liability
21.
pursuant to this subsection (b) and subsection (d) shall be limited to the net amount received
by the Holder from the sale of the Registrable Securities.
(c) Each party entitled to indemnification under this Section 6.6 (the Indemnified Party)
shall give notice to the party required to provide indemnification (the Indemnifying Party)
promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may
be sought, and shall permit the Indemnifying Party (at its expense) to assume the defense of any
such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party,
who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified
Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may
participate in such defense at such Indemnified Partys expense, and provided further that the
failure of any Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Article 6, unless such failure is materially
prejudicial to the Indemnifying Party in defending such claim or litigation and in any event shall
not relieve the Indemnifying Party from any liability which it may have otherwise then on account
of this Article 6. Notwithstanding the foregoing, the Indemnified Party shall have the right to
assume the defense at the Indemnifying Partys expense of any such claim or any litigation
resulting therefrom if (i) the Indemnifying Party and the Indemnified Party shall have mutually
agreed to the retention of such counsel by the Indemnified Party or (ii) the named parties to any
such proceeding (including any impleaded parties) include both the Indemnifying Party and the
Indemnified Party and the Indemnified Party shall have reasonably concluded that representation of
both the Indemnifying Party and the Indemnified Party by the same counsel would be inappropriate
due to actual or potential differing interests between them. It is understood that the
Indemnifying Party shall not, in respect of the legal expenses of any Indemnified Party in
connection with any proceeding or related proceedings in the same jurisdiction, be liable for the
fees and expenses of more than one separate firm (in addition to any local counsel) for all
Indemnified Parties and that all such fees and expenses shall be reimbursed as they are incurred.
Such firm shall be designated by the Company, in the case of the Indemnified Parties pursuant to
Section 6.6(a), and by a majority in interest of the Indemnified Parties, in the case of indemnity
pursuant to Section 6.6(b) hereof. An Indemnifying Party shall not be liable for any settlement of
an action or claim effected without its written consent (which consent will not be unreasonably
withheld). No Indemnifying Party, in its defense of any such claim or litigation, shall, except
with the consent of each Indemnified Party, consent to entry of any judgment or enter into any
settlement which does not include as an unconditional term thereof the giving by the claimant or
plaintiff to each Indemnified Party of a release from all liability in respect to such claim or
litigation.
(d) If the indemnification provided for in this Section 6.6 is unavailable to an Indemnified
Party or is insufficient with respect to any loss, liability, claim, damage or expense referred to
therein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party thereunder,
shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss,
liability, claim, damage or expense in such proportion as is appropriate to reflect the relative
fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in
connection with the statements or omissions or other matter that resulted in such loss, liability,
claim, damage or expense as well as any other relevant equitable considerations. The relative
fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of a material
22.
fact or the omission or alleged omission to state a material fact relates to information
supplied by the Indemnifying Party or by the Indemnified Party and the parties relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission.
6.7 (a) Each Holder agrees that, upon receipt of any notice from the Company of the happening
of any event requiring the preparation of a supplement or amendment to a prospectus relating to
Registrable Securities so that, as thereafter delivered to the Holders, such prospectus shall not
contain an untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading, each Holder will
forthwith discontinue disposition of Registrable Securities pursuant to the Registration Statement
and prospectus contemplated by Section 6.1 until its receipt of copies of the supplemented or
amended prospectus from the Company or notice from the Company that the use of the existing
prospectus may be resumed and, if so directed by the Company, each Holder shall deliver to the
Company all copies, other than permanent file copies then in such Holders possession, of the
prospectus covering such Registrable Securities current at the time of receipt of such notice.
(b) Each Holder shall suspend, upon written request of the Company, any disposition of
Registrable Securities pursuant to the Registration Statement and prospectus contemplated by
Section 6.1 during no more than two periods of no more than 30 calendar days each during any
12-month period to the extent that the Board of Directors of the Company determines in good faith
based on the advice of counsel that the sale of Registrable Securities under the Registration
Statement would be reasonably likely to cause a violation of the Securities Act or Exchange Act.
(c) As a condition to the inclusion of its Registrable Securities, each Holder shall furnish
to the Company such information regarding such Holder and the distribution proposed by such Holder
as the Company may reasonably request in writing, including completing a Registration Statement
questionnaire in the form provided by the Company, or as shall be required in connection with any
registration referred to in this Article 6.
(d) Each Holder, severally and not jointly, hereby covenants with the Company that such Holder
will not make any sale of the Registrable Securities without effectively causing the prospectus
delivery requirements under the Securities Act to be satisfied unless such sale is exempt from
registration.
(e) Each Holder acknowledges and agrees that the Registrable Securities sold pursuant to the
Registration Statement are not transferable on the books of the Company unless the stock
certificate submitted to the transfer agent evidencing such Registrable Securities is accompanied
by a certificate reasonably satisfactory to the Company to the effect that (i) the Registrable
Securities have been sold in accordance with such Registration Statement and (ii) the requirement
of delivering a current prospectus has been satisfied.
(f) Each Holder, severally and not jointly, agrees not to take any action with respect to any
distribution deemed to be made pursuant to such Registration Statement which would constitute a
violation of Regulation M under the Exchange Act or any other applicable rule, regulation or law.
23.
(g) At the end of the Registration Period the Holders shall discontinue sales of shares
pursuant to such Registration Statement upon receipt of notice from the Company of its intention to
remove from registration the shares covered by such Registration Statement which remain unsold, and
such Holders shall notify the Company of the number of shares registered which remain unsold as
soon as practical upon receipt of such notice from the Company.
6.8 With a view to making available to the Holders the benefits of certain rules and
regulations of the SEC which at any time permit the sale of the Registrable Securities to the
public without registration, so long as the Holders still own Registrable Securities, the Company
shall use its reasonable best efforts to:
(a) make and keep public information available, as those terms are understood and defined in
Rule 144 under the Securities Act, at all times;
(b) file with the SEC in a timely manner all reports and other documents required of the
Company under the Exchange Act; and
(c) so long as a Holder owns any Registrable Securities, furnish to such Holder, upon any
reasonable request, a written statement by the Company as to its compliance with Rule 144 under the
Securities Act, and of the Exchange Act, a copy of the most recent annual or quarterly report of
the Company, and such other reports and documents of the Company as such Holder may reasonably
request in availing itself of any rule or regulation of the SEC allowing a Holder to sell any such
securities without registration.
6.9 The rights to cause the Company to register Registrable Securities granted to the Holders
by the Company under Section 6.1 deemed to be transferred to a Holder in connection with a transfer
by such Holder of all or a portion of its Registrable Securities, provided, however, that (i) such
transfer may otherwise be effected in accordance with applicable securities laws; (ii) such Holder
gives prior written notice to the Company; and (iii) such transferee agrees to comply with the
terms and provisions of this Agreement, and such transfer is otherwise in compliance with this
Agreement. Except as specifically permitted by this Section 6.9, the rights of a Holder with
respect to Registrable Securities as set out herein shall not be transferable to any other Person,
and any attempted transfer shall cause all rights of such Holder therein to be forfeited.
6.10 The rights of any Holder under any provision of this Article 6 may be waived (either
generally or in a particular instance, either retroactively or prospectively and either for a
specified period of time or indefinitely) or amended by an instrument in writing signed by such
Holder.
ARTICLE 7
DEFINITIONS
7.1 Affiliate means, with respect to any Person, any other Person controlling, controlled by
or under direct or indirect common control with such Person (for the purposes of this definition
control, when used with respect to any specified Person, shall mean the power to direct the
management and policies of such Person, directly or indirectly, whether through
24.
ownership of voting securities, by contract or otherwise; and the terms controlling and
controlled shall have meanings correlative to the foregoing).
7.2 Business Day means a day Monday through Friday on which banks are generally open for
business in New York City.
7.3 Bylaws has the meaning set forth in Section 2.4.
7.4 Certificate of Incorporation has the meaning set forth in Section 2.4.
7.5 Closing has the meaning set forth in Section 1.3.
7.6 Closing Date has the meaning set forth in Section 1.3.
7.7 Common Stock means the common stock, par value $0.01 per share, of the Company.
7.8 Company means MannKind Corporation, a Delaware corporation.
7.9 Exchange Act means the Securities Exchange Act of 1934, as amended.
7.10 Filing Date has the meaning set forth in Section 6.1.
7.11 Final Prospectus has the meaning set forth in Section 6.6(a).
7.12 Financial Statements means the financial statements of the Company included in the SEC
Documents.
7.13 Holder means any Person holding Registrable Securities or any person to whom the rights
under Article 6 have been transferred in accordance with Section 6.9 hereof.
7.14 Indemnified Party has the meaning set forth in Section 6.6(c).
7.15 Indemnifying Party has the meaning set forth in Section 6.6(c).
7.16 Intellectual Property has the meaning set forth in Section 2.11.
7.17 Material Adverse Effect means a material adverse effect on (a) the business, assets,
financial condition, results of operations or prospects (as described in the SEC Documents as of
the date of this Agreement) of the Company and its Subsidiaries, taken as a whole, or (b) the
ability of the Company to perform its obligations pursuant to the transactions contemplated by this
Agreement.
7.18 Nasdaq means The Nasdaq National Market.
7.19 Offering means the private placement of the Companys Securities contemplated by this
Agreement.
7.20 Penalty Period has the meaning set forth in Section 6.3.
25.
7.21 Person or person means any person, individual, corporation, limited liability
company, partnership, trust or other nongovernmental entity or any governmental agency, court,
authority or other body (whether foreign, federal, state, local or otherwise).
7.22 Placement Agents means, collectively, Wachovia Capital Markets, LLC and Leerink Swann &
Company.
7.23 Purchasers mean the Purchasers whose names are set forth on the signature pages of this
Agreement, and their permitted transferees.
7.24 Purchase Price has the meaning set forth in Section 1.1.
7.25 Registrable Securities means (i) the Shares and (ii) the Warrant Shares; provided,
however, that securities shall only be treated as Registrable Securities if and only for so long as
they (A) have not been disposed of pursuant to a registration statement that is effective under the
Securities Act, (B) have not been sold in a transaction exempt from the registration and prospectus
delivery requirements of the Securities Act so that all transfer restrictions and restrictive
legends with respect thereto are removed upon the consummation of such sale, (C) are held by a
Purchaser or any permitted transferee and (D) are not eligible to be sold pursuant to Rule 144(k)
promulgated under the Securities Act.
7.26 Registration Default has the meaning set forth in Section 6.3.
7.27 Registration Expenses means all expenses incurred by the Company in complying with
Section 6.1 hereof, including, without limitation, all registration, qualification and filing fees,
printing expenses, escrow fees, fees and expenses of counsel and auditors for the Company, blue sky
fees and expenses and the expense of any special audits incident to or required by any such
registration (but excluding the fees of legal counsel for any Holder).
7.28 Registration Statement has the meaning set forth in Section 6.1. As used herein, all
references to the Registration Statement, any prospectus and any amendments or supplements to any
of the foregoing shall be deemed to include all documents incorporated or deemed to be incorporated
by reference therein from time to time, and all references to information which is contained or
included in the Registration Statement or any such prospectus, amendment or supplement shall
include all such information that is incorporated or deemed to be incorporated by reference
therein.
7.29 Registration Period has the meaning set forth in Section 6.4(a).
7.30 Rule 144 means Rule 144 promulgated under the Securities Act, or any successor rule.
7.31 SEC means the United States Securities and Exchange Commission.
7.32 SEC Documents has the meaning set forth in Section 2.7.
7.33 Securities has the meaning set forth in Section 1.1.
26.
7.34 Securities Act means the Securities Act of 1933, as amended, and the rules and
regulations thereunder, or any similar successor statute.
7.35 Selling Expenses means all selling commissions applicable to the sale of Registrable
Securities by any Holder and all related fees and expenses of legal counsel for any Holder.
7.36 Shares has the meaning set forth in Section 1.1.
7.37 Subsidiary of any person shall mean any corporation, partnership, limited liability
company, joint venture or other legal entity of which such person and/or one or more other
Subsidiaries of such person owns, directly or indirectly, more than 50% of the stock or other
equity interests the holders of which are generally entitled to vote for the election of the board
of directors or other governing body of such corporation or other legal entity.
7.38 Warrant Shares has the meaning set forth in Section 2.5.
7.39 Warrants has the meaning set forth in Section 1.1.
ARTICLE 8
GOVERNING LAW; MISCELLANEOUS
8.1 Governing Law; Jurisdiction. This Agreement will be governed by and interpreted in
accordance with the laws of the State of New York without regard to the principles of conflict of
laws.
8.2 Counterparts; Signatures by Facsimile. This Agreement may be executed in two or more
counterparts, all of which are considered one and the same agreement and will become effective when
counterparts have been signed by each party and delivered to the other parties. This Agreement,
once executed by a party, may be delivered to the other parties hereto by facsimile transmission of
a copy of this Agreement bearing the signature of the party so delivering this Agreement.
8.3 Headings. The headings of this Agreement are for convenience of reference only, are not
part of this Agreement and do not affect its interpretation.
8.4 Severability. If any provision of this Agreement is invalid or unenforceable under any
applicable statute or rule of law, then such provision will be deemed modified in order to conform
with such statute or rule of law. Any provision hereof that may prove invalid or unenforceable
under any law will not affect the validity or enforceability of any other provision hereof.
8.5 Entire Agreement; Amendments. This Agreement (including all schedules and exhibits
hereto) and the certificates evidencing the Warrants constitute the entire agreement among the
parties hereto with respect to the subject matter hereof and thereof. There are no restrictions,
promises, warranties or undertakings, other than those set forth or referred to herein or therein.
This Agreement supersedes all prior agreements and understandings among the
27.
parties hereto with respect to the subject matter hereof. No provision of this Agreement may
be waived or amended other than by an instrument in writing signed by the party to be charged with
such waiver or amendment.
8.6 Notices. All notices required or permitted hereunder shall be in writing and shall be
deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by
confirmed facsimile if sent during normal business hours of the recipient, if not, then on the next
business day, (c) five days after having been sent by registered or certified mail, return receipt
requested, postage prepaid, or (d) one business day after deposit with a nationally recognized
overnight courier, specifying next day delivery, with written verification of receipt. The
addresses for such communications are:
|
|
|
|
|
|
|
If to the Company:
|
|
MannKind Corporation |
|
|
|
|
Attn: 28903 North Avenue Payne |
|
|
|
|
Valencia, CA 91355 |
|
|
|
|
|
|
|
With a copy to:
|
|
Cooley Godward llp |
|
|
|
|
4401 Eastgate Mall |
|
|
|
|
San Diego, CA 92121 |
|
|
|
|
Attn: D. Bradley Peck |
If to a Purchaser: To the address set forth immediately below such Purchasers name on the
signature pages hereto. Each party will provide ten days advance written notice to the other
parties of any change in its address.
8.7 Successors and Assigns. This Agreement is binding upon and inures to the benefit of the
parties and their successors and assigns. The Company will not assign this Agreement or any rights
or obligations hereunder without the prior written consent of the Purchasers, and no Purchaser may
assign this Agreement or any rights or obligations hereunder without the prior written consent of
the Company, except as permitted in accordance with Section 6.9 hereof.
8.8 Third Party Beneficiaries. This Agreement is intended for the benefit of the parties
hereto, Holders, their respective permitted successors and assigns and the Placement Agents, and is
not for the benefit of, nor may any provision hereof be enforced by, any other person.
8.9 Further Assurances. Each party will do and perform, or cause to be done and performed,
all such further acts and things, and will execute and deliver all other agreements, certificates,
instruments and documents, as another party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.
8.10 No Strict Construction. The language used in this Agreement is deemed to be the language
chosen by the parties to express their mutual intent, and no rules of strict construction will be
applied against any party.
28.
8.11 Equitable Relief. The Company recognizes that, if it fails to perform or discharge any
of its obligations under this Agreement, any remedy at law may prove to be inadequate relief to the
Purchasers or Holders. The Company therefore agrees that the Purchasers or Holders are entitled
to seek temporary and permanent injunctive relief in any such case. Each Purchaser also recognizes
that, if it fails to perform or discharge any of its obligations under this Agreement, any remedy
at law may prove to be inadequate relief to the Company. Each Purchaser therefore agrees that the
Company is entitled to seek temporary and permanent injunctive relief in any such case.
8.12 Survival of Representations and Warranties. Notwithstanding any investigation made by
any party to this Agreement, all representations and warranties made by the Company and the
Purchasers herein shall survive for a period of one year following the date hereof.
8.13 Independent Nature of Purchasers Obligations and Rights. Anything herein to the
contrary notwithstanding, the representations, warranties, covenants and agreements of each
Purchaser under this Agreement are several and not joint with the representations, warranties,
covenants and agreements of any other Purchaser, and no Purchaser shall be responsible in any way
for the performance of the obligations of any other Purchaser under this Agreement. Nothing
contained herein and no action taken by any Purchaser pursuant thereto, shall be deemed to
constitute the Purchasers as a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Purchasers are in any way acting in concert or as a group,
or are deemed Affiliates with respect to such obligations or the transactions contemplated by this
Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights,
including without limitation the rights arising out of this Agreement, and it shall not be
necessary for any other Purchaser to be joined as an additional party in any proceeding for such
purpose.
[Signature Page Follows]
29.
In Witness Whereof, the undersigned Purchasers and the Company have caused this
Agreement to be duly executed as of the date first above written.
|
|
|
|
|
|
|
MannKind Corporation |
|
|
|
|
|
|
|
By: |
|
/s/ HAKAN EDSTROM |
|
|
|
|
|
|
|
Name: |
|
Hakan Edstrom |
|
|
|
|
|
|
|
Title: |
|
President / COO |
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Adage Capital Partners,
L.P. |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ DANIEL J. LEHAN III |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
|
|
|
|
|
|
Daniel J. Lehan III, COO |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
200 Clarendon St., 52nd Flr. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Boston, MA 02116 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
617-867-2801 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
Custodial Trust Company |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
Custodial Trust Company |
|
|
|
|
|
|
|
|
|
|
|
|
|
101 Carnegie Center |
|
|
|
|
|
|
|
|
|
|
|
|
|
Princeton, NJ 08540-6231 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attn: Kevin Darmody |
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Alfred E. Mann Living
Trust |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ ALFRED E. MANN |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
|
|
|
|
|
|
Alfred E. Mann, Trustee |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
12744 San Fernando |
|
|
|
|
|
|
|
|
|
|
|
|
|
Sylmar, CA 91342 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
Merrill Lynch |
|
|
|
|
|
|
|
|
|
|
|
|
|
c/o Richard Jones |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
|
|
|
|
Biomed Partners, LLC |
|
|
|
|
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ ALFRED E. MANN |
|
By:
|
|
/s/ ALFRED E. MANN |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
(signature) |
|
|
|
|
|
|
|
|
|
Alfred E. Mann, President, Mimimed Infusion, Inc. Managing
Member |
|
|
|
Alfred E. Mann, Trustee
of the Alfred E. Mann Living Trust UAD 4/9/1999, Managing Member |
|
|
|
|
|
(print name and title) |
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Address: |
|
c/o Anoosheh Bostani |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12744 San Fernando Road |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sylmar, CA 91342 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(818) 788-7141 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
c/o Richard Jones |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Merrill Lynch Private Banking and
Investment Group |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
|
|
2049 Century Park East |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
South Tower, 12th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Los Angeles, CA 90067 |
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Amaranth Global
Equities Master Fund Limited,
By Amaranth Advisors, L.L.C., its Trading Advisor |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ KARL J. WACHTER, SVC |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Karl J. Wachter,
Authorized Signatory |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
One American Lane |
|
|
|
|
|
|
|
|
|
|
|
|
|
Greenwich, CT 06831 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(203) 422-3540 |
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Amaranth LLC, By
Amaranth Advisors L.L.C., its Trading Advisor |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ KARL J. WACHTER, SVC |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Karl J. Wachter,
Authorized Signatory |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
One American Lane |
|
|
|
|
|
|
|
|
|
|
|
|
|
Greenwich, CT 06831 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(203) 422-3540 |
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Atlas Master Fund, Ltd. |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ SCOTT SCHROEDER |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Scott Schroeder,
Authorized Signatory |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
c/o Balyasny Asset Management |
|
|
|
|
|
|
|
|
|
|
|
|
|
650 Madison Ave - 19th Fl. |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
212-808-2301 |
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Brookside Capital
Partners Fund, L.P. |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ MATT McPHERSON |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Matt McPherson,
Managing Director |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
D3 LifeScience Ltd. |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
D3 LifeScience Market
Neutral Ltd. |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
D3 LifeScience Select Ltd. |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ NATHAN FISCHEL |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Nathan Fischel, MD,
CFA, Managing Member |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
c/o D3 Capital Management, LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
10990 Wilshire Blvd., Suite 1400 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Los Angeles, CA 90024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(310) 481-0722 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
Bear, Stearns Securities Corp. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
Bear, Stearns Securities Corp. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attn: Christine Bell |
|
|
|
|
|
|
|
|
|
|
|
|
|
1999 Avenue of the Stars,
Suite 2530 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Los Angeles, CA 90067 |
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Deerfield International
Limited |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ DARREN LEVINE |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Darren Levine, CFO |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
780 3rd Ave |
|
|
|
|
|
|
|
|
|
|
|
|
|
37th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
212-599-1248 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
Morgan Stanley |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
Please deliver directly to us - |
|
|
|
|
|
|
|
|
|
|
|
|
|
Use the address above |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Deerfield Partners, LP |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ DARREN LEVINE |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Darren Levine, CFO |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
780 3rd Ave |
|
|
|
|
|
|
|
|
|
|
|
|
|
37th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
212-599-1248 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
Morgan Stanley |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
Please deliver to address above - directly to us |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Fidelity Contrafund |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ JOHN H. COSTELLO |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
John H. Costello,
Assistant Treasurer |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
82 Devonshire Street, E31C |
|
|
|
|
|
|
|
|
|
|
|
|
|
Boston, MA 02109 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attn: Andrew Boyd, Esq. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
617-476-5174 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
Certificate to be registered in the
name of: MAG & CO. FBO Fidelity
Contrafund |
|
|
|
|
|
|
|
|
|
|
|
|
|
Brown Brothers Harriman |
|
|
|
|
|
|
|
|
|
|
|
|
|
140 Broadway |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10005-1101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Fidelity Contrafund, Act 811157-7 |
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Fidelity Contrafund: Fidelity Advisor New Insights Fund |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ JOHN H. COSTELLO |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
John H. Costello,
Assistant Treasurer |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
82 Devonshire Street, E31C |
|
|
|
|
|
|
|
|
|
|
|
|
|
Boston, MA 02109 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attn: Andrew Boyd, Esq. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
617-476-5174 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
Certificate to be registered in the
name of: MAG & CO. FBO Fidelity Contrafund: Fidelity Advisor New
Insights Fund |
|
|
|
|
|
|
|
|
|
|
|
|
|
Brown Brothers Harriman |
|
|
|
|
|
|
|
|
|
|
|
|
|
140 Broadway |
|
|
|
|
|
|
|
|
|
|
|
|
|
Fidelity Contrafund: Fidelity
Advisor New Insights Fund |
|
|
|
|
|
|
|
|
|
|
|
|
|
Act 615776-2 |
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Variable Insurance
Products Fund II: Contrafund Portfolio |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ JOHN H. COSTELLO |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
John H. Costello,
Assistant Treasurer |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
82 Devonshire Street, E31C |
|
|
|
|
|
|
|
|
|
|
|
|
|
Boston, MA 02109 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attn: Andrew Boyd, Esq. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
617 476 5174 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
Certificate to be registered in the
name of: MAG & CO. FBO Variable Insurance Products Fund II: Contrafund
Portfolio |
|
|
|
|
|
|
|
|
|
|
|
|
|
Brown Brothers Harriman |
|
|
|
|
|
|
|
|
|
|
|
|
|
140 Broadway |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10005-1101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Variable Insurance Products Fund
II: Contrafund Portfolio |
|
|
|
|
|
|
|
|
|
|
|
|
|
Act 816683-7 |
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
The Edstrom Family Trust 3/1/1996 |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ HAKAN EDSTROM |
|
|
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Hakan Edstrom/Trustee |
|
|
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
23312 Happy Valley Dr. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Newhall, CA 91321 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
661-259-1636 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
Hakan Edstrom |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
Same as above |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Kresa Family Trust |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ KENT KRESA |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Kent Kresa, Trustee |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
11446 Tower Road |
|
|
|
|
|
|
|
|
|
|
|
|
|
Beverly Hills, CA 90210 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(310) 248-4383 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Kings Road Investments Ltd. |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ ERIK M. W. CASPERSEN |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Erik M. W. Caspersen, Authorized Signatory |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
c/o Polygon Investment Partners LP |
|
|
|
|
|
|
|
|
|
|
|
|
|
598 Madison Avenue, 14th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
212-359-7303 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
UBS Securities LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
Please deliver to Kings Road Investments Ltd. |
|
|
|
|
|
|
|
|
|
|
|
|
|
address above |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Narragansett I, LP |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ JOSEPH L. DOWLING, III |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Joseph L. Dowling, III/Managing Member |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
540 Madison Ave., 38th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(212) 813-5856 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
Bank of America |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
Bank of America |
|
|
|
|
|
|
|
|
|
|
|
|
|
9 West 57th St., 17th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attn: John Melnick |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10019 |
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Narragansett Offshore, Ltd. |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ JOSEPH L. DOWLING, III |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Joseph L. Dowling, III/Authorized Signature |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
540 Madison Ave. 38th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(212) 813-5856 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
Bank Of America |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
9 West 57th St., 17th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attn: John Melnick |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10019 |
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Oracle U.S. Partners, LLC |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ LARRY N. FEINBERG |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Larry N. Feinberg/Managing Member |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
200 Greenwich Avenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
Greenwich, CT 06830 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(203) 862-7982 |
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
ARIES DOMESTIC FUND, L.P. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
PARAMOUNT BIOCAPITAL ASSET MANAGEMENT, INC., its general partner |
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ LINDSAY A. ROSENWALD, M.D. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Name: Lindsay A. Rosenwald, M.D. Title: Chairman and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
Address: |
|
c/o Paramount BioCapital Asset Management, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
787 Seventh Avenue, 48th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, New York 10019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attention: General Counsel |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(212) 554-4355 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
ARIES DOMESTIC FUND II, L.P. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
PARAMOUNT BIOCAPITAL ASSET MANAGEMENT, INC., its general partner |
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ LINDSAY A. ROSENWALD, M.D. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Name: Lindsay A. Rosenwald, M.D. Title: Chairman and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Address: |
|
c/o Paramount BioCapital Asset Management, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
787 Seventh Avenue, 48th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, New York 10019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attention: General Counsel |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(212) 554-4355 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
ARIES MASTER FUND II |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
PARAMOUNT BIOCAPITAL ASSET MANAGEMENT, INC., its investment manager |
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ LINDSAY A. ROSENWALD, M.D. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Name: Lindsay A. Rosenwald, M.D. Title: Chairman and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Address: |
|
c/o Paramount BioCapital Asset Management, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
787 Seventh Avenue, 48th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, New York 10019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attention: General Counsel |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(212) 554-4355 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
RAQ, LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ LINDSAY A. ROSENWALD, M.D. |
|
|
|
|
|
|
|
|
|
Name: Lindsay A. Rosenwald, M.D. Title: Managing Member |
|
|
|
|
|
|
|
|
|
|
Address: |
|
c/o Paramount BioCapital Investments, LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
787 Seventh Avenue, 48th Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, New York 10019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attention: General Counsel |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(212) 554-4490 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
By: T. Rowe Price Associates, Inc.
on behalf of its participating clients on Schedule A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ JOHN H. LAPORTE |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
John H. Laporte, Vice President |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
c/o T. Rowe Price Associates, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
100 East Pratt Street |
|
|
|
|
|
|
|
|
|
|
|
|
|
Balitmore, Maryland 21202 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
410-345-6575 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
See attached Schedule A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
See attached Schedule A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
SCHEDULE A
T. Rowe Price Participating Funds
|
|
|
|
|
|
John Hancock Trust Health Sciences Trust |
|
|
T. Rowe Price Health Sciences Portfolio, Inc. |
|
|
|
|
|
|
Nominee Name Lamppost & Co. |
|
|
Nominee Name HorizonBeach & Co. |
|
|
|
|
|
|
Delivery Instructions: |
|
|
Delivery Instructions: |
State Street Bank |
|
|
State Street Bank |
New York Settlements |
|
|
New York Settlements |
DTC/NY Window |
|
|
DTC/NY Window |
55 Water Street |
|
|
55 Water Street |
New York, NY 10041 |
|
|
New York, NY 10041 |
Attn: Robert Mendez |
|
|
Attn: Robert Mendez |
|
|
|
|
|
|
|
|
|
|
|
|
|
TD
Mutual Funds TD Health Sciences Fund |
|
|
VALIC Company I Health Sciences Fund |
|
|
|
|
|
|
Nominee Name
Mac & Co. |
|
|
Nominee Name Squidrig & Co. |
|
|
|
|
|
|
Delivery Instructions: |
|
|
Delivery Instructions: |
Physical Deliveries New York |
|
|
State Street Bank |
Mellon Securities Trust Co. |
|
|
New York Settlements |
120 Broadway, 13th Floor |
|
|
DTC/NY Window |
New York, NY 10271 |
|
|
55 Water Street |
|
|
|
New York, NY 10041 |
|
|
|
Attn: Robert Mendez |
|
|
|
|
|
|
|
|
|
|
|
|
|
Raytheon
Company Combined DB/DC Master Trust
Health Sciences |
|
|
TA IDEX T. Rowe Price Health Sciences |
|
|
|
|
|
|
Nominee Name
BOST & Co. |
|
|
Nominee Name Hare & Co. |
|
|
|
|
|
|
Delivery Instructions: |
|
|
Delivery Instructions: |
Mellon Securities Trust Co. |
|
|
Bank of New York |
120 Broadway, 13th Floor |
|
|
One Wall Street |
New York, NY 10271 |
|
|
Window A |
|
|
|
New York, NY 10286 |
|
|
|
|
|
|
|
|
|
|
|
|
|
T. Rowe Price Health Sciences Fund, Inc. |
|
|
T. Rowe Price New Horizons Fund, Inc. |
|
|
|
|
|
|
Nominee Name
Lobstercrew & Co. |
|
|
Nominee Name Bridge & Co. |
|
|
|
|
|
|
Delivery Instructions: |
|
|
Delivery Instructions: |
State Street Bank |
|
|
State Street Bank |
New York Settlements |
|
|
New York Settlements |
DTC/NY Window |
|
|
DTC/NY Window |
55 Water Street |
|
|
55 Water Street |
New York, NY 10041 |
|
|
New York, NY 10041 |
Attn: Robert Mendez |
|
|
Attn: Robert Mendez |
|
|
|
|
|
|
|
|
|
Purchaser |
|
|
|
|
|
|
|
|
|
Tang Capital Partners, LP |
|
|
|
|
|
|
|
(investor name) |
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ KEVIN C. TANG |
|
|
|
|
|
|
|
|
|
(signature) |
|
|
|
|
|
Kevin C. Tang, Managing Member |
|
|
|
|
|
|
|
(print name and title) |
|
|
|
|
|
|
|
|
|
Address: |
|
4401 Eastgate Mall |
|
|
|
|
|
|
|
|
|
|
|
|
|
San Diego, CA 92121 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facsimile: |
|
(858) 200-3837 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodian: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Custodians address for
delivery of Securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement
Signature Page
EXHIBIT A
SCHEDULE OF PURCHASERS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate Purchase |
Purchaser |
|
Shares |
|
Warrants |
|
Price |
Adage Capital Partners, LP |
|
|
1,076,848 |
|
|
|
215,370 |
|
|
$ |
11,000,002.32 |
|
Alfred E. Mann, as Trustee of the Alfred E.
Mann Living Trust Dated April 19, 1999 |
|
|
6,944,963 |
|
|
|
1,388,993 |
|
|
$ |
70,942,797.05 |
|
Biomed Partners, LLC. |
|
|
1,605,483 |
|
|
|
321,098 |
|
|
$ |
16,400,008.85 |
|
Amaranth Global Equities Master Fund Limited |
|
|
34,263 |
|
|
|
6,853 |
|
|
$ |
349,996.55 |
|
Amaranth LLC |
|
|
308,371 |
|
|
|
61,674 |
|
|
$ |
3,150,009.77 |
|
Atlas Master Fund, Ltd. |
|
|
293,686 |
|
|
|
58,737 |
|
|
$ |
3,000,002.49 |
|
Brookside Capital Partners Fund, L.P. |
|
|
1,272,639 |
|
|
|
254,528 |
|
|
$ |
13,000,007.39 |
|
D3 LifeScience Ltd |
|
|
105,554 |
|
|
|
21,111 |
|
|
$ |
1,078,234.11 |
|
D3 LifeScience Market Neutral Ltd. |
|
|
58,900 |
|
|
|
11,780 |
|
|
$ |
601,663.50 |
|
D3 LifeScience Select Ltd. |
|
|
31,337 |
|
|
|
6,267 |
|
|
$ |
320,107.46 |
|
Deerfield International Limited |
|
|
407,245 |
|
|
|
81,449 |
|
|
$ |
4,160,007.68 |
|
Deerfield Partners, L.P. |
|
|
375,918 |
|
|
|
75,184 |
|
|
$ |
3,840,002.37 |
|
Fidelity Contrafund |
|
|
1,521,689 |
|
|
|
304,338 |
|
|
$ |
15,544,053.14 |
|
Fidelity Contrafund: Fidelity Advisor New
Insights Fund |
|
|
149,406 |
|
|
|
29,881 |
|
|
$ |
1,526,182.29 |
|
Variable Insurance Products Fund II: |
|
|
|
|
|
|
|
|
|
|
|
|
Contrafund Portfolio |
|
|
433,653 |
|
|
|
86,731 |
|
|
$ |
4,429,765.40 |
|
The Edstrom Family Trust 3/1/1996 |
|
|
4,895 |
|
|
|
979 |
|
|
$ |
50,002.43 |
|
Kresa Family Trust DTD 10/6/87 Kent Kresa,
Trustee |
|
|
10,500 |
|
|
|
2,100 |
|
|
$ |
107,257.50 |
|
Kings Road Investments Ltd. |
|
|
391,582 |
|
|
|
78,316 |
|
|
$ |
4,000,010.13 |
|
Narragansett I, LP |
|
|
297,602 |
|
|
|
59,521 |
|
|
$ |
3,040,004.43 |
|
Narragansett Offshore, Ltd. |
|
|
485,561 |
|
|
|
97,112 |
|
|
$ |
4,960,005.62 |
|
Oracle US Partners LLC |
|
|
440,529 |
|
|
|
88,106 |
|
|
$ |
4,500,003.74 |
|
Aries Domestic Fund, L.P. |
|
|
41,850 |
|
|
|
8,370 |
|
|
$ |
427,497.75 |
|
Aries Domestic Fund II, L.P. |
|
|
7,342 |
|
|
|
1,468 |
|
|
$ |
74,998.53 |
|
Aries Master Fund II |
|
|
24,229 |
|
|
|
4,846 |
|
|
$ |
247,499.24 |
|
RAQ, LLC |
|
|
73,422 |
|
|
|
14,685 |
|
|
$ |
750,005.73 |
|
John Hancock Trust Health Sciences Trust |
|
|
21,000 |
|
|
|
4,200 |
|
|
$ |
214,515.00 |
|
Raytheon Company Combined DB/DC Master Trust
- - Health Sciences |
|
|
4,900 |
|
|
|
980 |
|
|
$ |
50,053.50 |
|
T. Rowe Price New Horizons Fund, Inc. |
|
|
314,000 |
|
|
|
62,800 |
|
|
$ |
3,207,510.00 |
|
T. Rowe Price Health Sciences Fund, Inc. |
|
|
130,000 |
|
|
|
26,000 |
|
|
$ |
1,327,950.00 |
|
T. Rowe Price Health Sciences Portfolio, Inc. |
|
|
900 |
|
|
|
180 |
|
|
$ |
9,193.50 |
|
TA IDEX T. Rowe Price Health Sciences |
|
|
30,624 |
|
|
|
6,125 |
|
|
$ |
312,824.16 |
|
TD Mutual Funds TD Health Sciences Fund |
|
|
22,000 |
|
|
|
4,400 |
|
|
$ |
224,730.00 |
|
VALIC Company I Health Sciences Fund |
|
|
15,000 |
|
|
|
3,000 |
|
|
$ |
153,225.00 |
|
Tang Capital Partners, LP |
|
|
195,791 |
|
|
|
39,158 |
|
|
$ |
2,000,005.07 |
|
Total: |
|
|
17,131,682 |
|
|
|
3,426,340 |
|
|
$ |
175,000,131.70 |
|
EXHIBIT B
FORM OF WARRANT
THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT
BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS OR UNLESS
OFFERED, SOLD, PLEDGED, HYPOTHECATED OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM OR IN A
TRANSACTION NOT SUBJECT TO THE REGISTRATION REQUIREMENTS OF THOSE LAWS. THE COMPANY SHALL BE
ENTITLED TO REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED TO THE EXTENT THAT AN OPINION IS REQUIRED PURSUANT TO THAT CERTAIN
SECURITIES PURCHASE AGREEMENT UNDER WHICH THE SECURITIES WERE ISSUED.
MannKind Corporation
WARRANT TO PURCHASE COMMON STOCK
|
|
|
No. CW-___
|
|
August 5, 2005 |
Void After August 5, 2010
This Certifies That, for value received, , with its principal
office at , or its assigns (the Holder), is entitled to
subscribe for and purchase at the Exercise Price (defined below) from MannKind Corporation, a
Delaware corporation, with its principal office at 28903 North Avenue Payne, Valencia, CA 91355
(the Company) up to shares of the Common Stock of the Company (the Common Stock),
subject to adjustment as provided herein. This Warrant is one of a series of Warrants being issued
pursuant to the terms of the Securities Purchase Agreement, dated August 2, 2005, by and among the
Company and the original Holder of this Warrant and the other parties named therein (the Purchase
Agreement). Capitalized terms not otherwise defined herein shall have the respective meanings
ascribed to such terms in the Purchase Agreement.
1. Definitions. As used herein, the following terms shall have the following
respective meanings:
(a) Exercise Period shall mean the period commencing 180 days after the date hereof and
ending August 5, 2010, unless sooner terminated as provided below.
(b) Exercise Price shall mean $12.228 per share, subject to adjustment pursuant to Section 6
below.
1.
(c) Exercise Shares shall mean the shares of the Companys Common Stock issuable upon
exercise of this Warrant, subject to adjustment pursuant to the terms herein, including but not
limited to adjustment pursuant to Section 6 below.
2. Exercise of Warrant.
2.1 Method of Exercise. The rights represented by this Warrant may be exercised in whole or
in part at any time during the Exercise Period, by delivery of the following to the Company at its
address set forth above (or at such other address as it may designate by notice in writing to the
Holder):
(a) An executed Notice of Exercise in the form attached hereto;
(b) Payment of the Exercise Price either (i) in cash or by check or wire transfer of
immediately available funds, or (ii) pursuant to a cashless exercise, as described below; and
(c) This Warrant.
Upon the exercise of the rights represented by this Warrant, shares of Common Stock shall be
issued for the Exercise Shares so purchased, and shall be registered in the name of the Holder or
persons affiliated with the Holder, if the Holder so designates, within three business days after
the receipt by the Company of all of the items designated in clauses (a), (b) and (c) above and
shall be issued in certificate form and delivered to the Holder, if so requested.
The person in whose name any Exercise Shares are to be issued upon exercise of this Warrant
shall be deemed to have become the holder of record of such shares on the date on which this
Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of
issuance of the shares of Common Stock, except that, if the date of such surrender and payment is a
date when the stock transfer books of the Company are closed, such person shall be deemed to have
become the holder of such shares at the close of business on the next succeeding date on which the
stock transfer books are open.
2.2 Cashless Exercise. Notwithstanding any provisions herein to the contrary, if, at any time
during the Exercise Period, the Current Market Price (as defined below) of one share of Common
Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu
of exercising this Warrant by payment of cash, the Holder may exercise this Warrant by a cashless
exercise by surrender of this Warrant at the principal office of the Company together with the
properly endorsed Notice of Exercise and the Company shall issue to the Holder a number of shares
of Common Stock computed using the following formula:
|
|
|
|
|
|
|
|
|
X =
|
|
Y (B-A)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
B |
|
|
|
|
|
|
|
|
|
Where: |
|
X = |
|
the number of shares of Common Stock to be issued to the Holder. |
|
|
|
|
|
|
|
|
|
Y = |
|
the number of shares of Common Stock purchasable upon
exercise of all of the Warrant or, if only a portion of the Warrant is being
exercised, the portion of the Warrant being exercised. |
2.
|
|
|
|
|
|
|
|
|
A = |
|
the Exercise Price as then in effect. |
|
|
|
|
|
|
|
|
|
B = |
|
the Current Market Price of one share of Common Stock. |
|
|
|
|
|
|
|
|
|
Current Market Price means on any particular date: |
(a) if the Common Stock is traded on the Nasdaq SmallCap Market or the Nasdaq National Market,
the average of the closing prices of the Common Stock of the Company on such market over the five
(5) trading days ending immediately prior to the applicable date of valuation (in the case of a
cashless exercise, the date of valuation shall be the exercise date);
(b) if the Common Stock is traded on any national stock exchange but is not traded on the
Nasdaq SmallCap Market or the Nasdaq National Market, the average of the closing prices of the
Common Stock of the Company on such exchange over the five (5) trading days ending immediately
prior to the applicable date of valuation;
(c) if the Common Stock is traded over-the-counter, but not on the Nasdaq SmallCap Market, the
Nasdaq National Market or a national stock exchange, the average of the closing bid prices over the
30-day period ending immediately prior to the applicable date of valuation; and
(d) if there is no active public market for the Common Stock, the value thereof, as determined
in good faith by the Board of Directors of the Company upon due consideration of the proposed
determination thereof by the Holder.
2.3 Partial Exercise. If this Warrant is exercised in part only, the Company shall, upon
surrender of this Warrant, execute and deliver, within 10 days of the date of exercise, a new
Warrant evidencing the rights of the Holder, or such other person as shall be designated in the
Notice of Exercise, to purchase the balance of the Exercise Shares purchasable hereunder. In no
event shall this Warrant be exercised for a fractional Exercise Share, and the Company shall not
distribute a Warrant exercisable for a fractional Exercise Share. Fractional Exercise Shares shall
be treated as provided in Section 5 hereof.
3. Covenants of the Company.
3.1 Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise
Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon
issuance, be duly authorized and validly issued and outstanding, fully paid and nonassessable, and
free from all taxes, liens and charges with respect to the issuance thereof. The Company further
covenants and agrees that the Company will at all times during the Exercise Period, have authorized
and reserved, free from preemptive or other similar rights, a sufficient number of shares of its
Common Stock to provide for the exercise of the rights represented by this Warrant. If at any time
during the Exercise Period the number of authorized but unissued shares of Common Stock shall not
be sufficient to permit exercise of this Warrant, the Company will take such corporate action as
may be necessary to increase its authorized but unissued shares of Common Stock (or other
securities as provided herein) to such number of shares as shall be sufficient for such purposes.
3.
3.2 No Impairment. Except and to the extent as waived or consented to by the Holder in
accordance with Section 10 hereof, the Company will not, by amendment of its Certificate of
Incorporation (as such may be amended from time to time), or through any means, avoid or seek to
avoid the observance or performance of any of the terms to be observed or performed hereunder by
the Company, but will at all times in good faith carry out of all the provisions of this Warrant
and take all such action as may be necessary or appropriate in order to protect the exercise rights
of the Holder against impairment.
3.3 Notices of Record Date. In the event of any taking by the Company of a record of the
holders of any class of securities for the purpose of determining the holders thereof who are
entitled to receive any dividend (other than a cash dividend which is the same as cash dividends
paid in previous quarters) or other distribution, the Company shall mail to the Holder, at least
ten days prior to the date specified herein, a notice specifying the date on which any such record
is to be taken for the purpose of such dividend or distribution.
4. Representations of Holder.
4.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that it
is acquiring the Warrant and the Exercise Shares solely for its account for investment and not with
a present view toward the public sale or public distribution of said Warrant or Exercise Shares or
any part thereof and has no intention of selling or distributing said Warrant or Exercise Shares or
any arrangement or understanding with any other persons regarding the sale or distribution of said
Warrant or the Exercise Shares, except as would not result in a violation of the Securities Act.
The Holder will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of
(or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) the Warrant
except in accordance with the Securities Act and will not, directly or indirectly, offer, sell,
pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise
acquire or take a pledge of) the Exercise Shares except in accordance with the provisions of
Article 6 of the Purchase Agreement or pursuant to and in accordance with the Securities Act.
4.2 Securities Are Not Registered.
(a) The Holder understands that the offer and sale of neither the Warrant nor the Exercise
Shares has been registered under the Securities Act.
(b) The Holder recognizes that the Warrant and the Exercise Shares must be held indefinitely
unless they are subsequently registered under the Securities Act or an exemption from such
registration is available. The Holder recognizes that the Company has no obligation to register
the Warrant or, except as provided in the Purchase Agreement, the Exercise Shares, or to comply
with any exemption from such registration.
(c) The Holder is aware that neither the Warrant nor the Exercise Shares may be sold pursuant
to Rule 144 adopted under the Securities Act unless certain conditions are met, including, among
other things, the availability of certain current public information about the Company and the
expiration of the required holding period under Rule 144.
4.
4.3 Disposition of Warrant and Exercise Shares.
(a) The Holder further agrees not to make any disposition of all or any part of the Warrant or
Exercise Shares in any event unless and until:
(i) The Company shall have received a letter secured by the Holder from the SEC stating that
no action will be recommended to the Commission with respect to the proposed disposition;
(ii) There is then in effect a registration statement under the Securities Act covering such
Warrant or Exercise Shares and such disposition is made in accordance with said registration
statement; or
(iii) The Holder shall have notified the Company of the proposed disposition and shall have
furnished the Company with a reasonably detailed statement of the circumstances surrounding the
proposed disposition in order for the Company to confirm compliance with the provisions of this
Warrant, the Purchase Agreement and applicable securities laws, if reasonably requested by the
Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably
satisfactory to the Company, for the Holder to the effect that such disposition will not require
registration of such Warrant or Exercise Shares under the Securities Act or any applicable state
securities laws; provided, that no opinion shall be required for any disposition made or to be made
in accordance with the provisions of Rule 144.
(b) The Holder understands and agrees that all certificates evidencing the Exercise Shares to
be issued to the Holder may bear a legend in substantially the following form (provided that no
such legend will be borne by Exercise Shares issued following the disposition of such shares
pursuant to a registration statement which is effective under the Securities Act and provided,
further, that the Company will remove such legend at the request of the Holder (i) following any
sale of the Exercise Shares pursuant to an effective registration statement or Rule 144, or (ii) if
such Exercise Shares are eligible for sale under Rule 144(k)):
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE
UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED,
HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS, OR UNLESS OFFERED,
SOLD, PLEDGED, HYPOTHECATED OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM
OR IN A TRANSACTION NOT SUBJECT TO THE REGISTRATION REQUIREMENTS OF THOSE
LAWS. THE COMPANY SHALL BE ENTITLED TO REQUIRE AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED TO THE EXTENT
THAT AN OPINION IS REQUIRED PURSUANT TO THE AGREEMENT UNDER WHICH THE SECURITIES
WERE ISSUED.
5.
5. Fractional Shares. No fractional shares shall be issued upon the exercise of this
Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including
fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining
whether the exercise would result in the issuance of any fractional share. If, after aggregation,
the exercise would result in the issuance of a fractional share, the Company shall, in lieu of
issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash
equal to the product resulting from multiplying the then Current Market Price (as of the applicable
exercise date) of an Exercise Share by such fraction.
6. Certain Events.
6.1 Distribution of Assets. In case the Company shall declare or make any distribution of its
assets (or rights to acquire its assets) to holders of Common Stock as a partial liquidating
dividend, by way of return of capital or otherwise (including any dividend or distribution to the
Companys stockholders of cash or shares (or rights to acquire shares) of capital stock of a
subsidiary) (a Distribution), at any time after the initial issuance of this Warrant, then the
Holder shall be entitled upon exercise of this Warrant for the purchase of any or all of the shares
of Common Stock subject hereto, to receive the amount of such assets (or rights) which would have
been payable to the Holder had such Holder been the holder of such shares of Common Stock on the
record date for the determination of stockholders entitled to such Distribution.
6.2 Dividends, Subdivisions, Combinations and Reclassifications. The number and kind of
securities purchasable upon the exercise of this Warrant and the Exercise Price shall be subject to
adjustment from time to time upon the happening of any of the following. In case the Company shall
(i) pay a dividend in shares of Common Stock or make a distribution in shares of Common Stock to
holders of its outstanding Common Stock, (ii) subdivide its outstanding shares of Common Stock into
a greater number of shares, (iii) combine its outstanding shares of Common Stock into a smaller
number of shares of Common Stock, or (iv) issue any shares of its capital stock in a
reclassification of the Common Stock, then the number of Warrant Shares purchasable upon exercise
of this Warrant immediately prior thereto shall be adjusted so that the Holder shall be entitled to
receive the kind and number of Warrant Shares or other securities of the Company which it would
have owned or have been entitled to receive had such Warrant been exercised in advance thereof.
Upon each such adjustment of the kind and number of Warrant Shares or other securities of the
Company which are purchasable hereunder, the Holder shall thereafter be entitled to purchase the
number of Warrant Shares or other securities resulting from such adjustment at an Exercise Price
per Warrant Share or other security obtained by multiplying the Exercise Price in effect
immediately prior to such adjustment by the number of Warrant Shares purchasable pursuant hereto
immediately prior to such adjustment and dividing by the number of Warrant Shares or other
securities of the Company resulting from such adjustment. An adjustment made pursuant to this
paragraph shall become effective immediately after the effective date of such event retroactive to
the record date, if any, for such event.
6.3 Reorganization, Reclassification, Merger, Consolidation or Disposition of Assets. In case
the Company shall reorganize its capital, reclassify its capital stock, consolidate or merge with
or into another corporation (where the Company is not the
6.
surviving corporation or where there is a change in or distribution with respect to the Common
Stock of the Company), or sell, transfer or otherwise dispose of all or substantially all its
property, assets or business to another corporation and, pursuant to the terms of such
reorganization, reclassification, merger, consolidation or disposition of assets, shares of common
stock of the successor or acquiring corporation, or any cash, shares of stock or other securities
or property of any nature whatsoever (including warrants or other subscription or purchase rights)
in addition to or in lieu of common stock of the successor or acquiring corporation (Other
Property), are to be received by or distributed to the holders of Common Stock of the Company,
then the Holder shall have the right thereafter to receive upon exercise of this Warrant, the
number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it
is the surviving corporation, and Other Property receivable upon or as a result of such
reorganization, reclassification, merger, consolidation or disposition of assets by a Holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such
event. In case of any such reorganization, reclassification, merger, consolidation or disposition
of assets, the successor or acquiring corporation (if other than the Company) shall expressly
assume the due and punctual observance and performance of each and every covenant and condition of
this Warrant to be performed and observed by the Company and all the obligations and liabilities
hereunder, subject to such modifications as may be deemed appropriate (as determined in good faith
by resolution of the Board of Directors of the Company) in order to provide for adjustments of
Warrant Shares for which this Warrant is exercisable which shall be as nearly equivalent as
practicable to the adjustments provided for in this Section 6.3. For purposes of this Section 6.3,
common stock of the successor or acquiring corporation shall include stock of such corporation of
any class which is not preferred as to dividends or assets over any other class of stock of such
corporation and which is not subject to redemption and shall also include any evidences of
indebtedness, shares of stock or other securities which are convertible into or exchangeable for
any such stock, either immediately or upon the arrival of a specified date or the happening of a
specified event and any warrants or other rights to subscribe for or purchase any such stock. The
foregoing provisions of this Section 6.3 shall similarly apply to successive reorganizations,
reclassifications, mergers, consolidations or disposition of assets.
6.4 Adjustment of Exercise Price. The form of this Warrant need not be changed
because of any adjustment in the number, class, and kind of shares or Other Property subject to
this Warrant. The Company shall promptly provide a certificate from its principal accounting
officer notifying the Holder in writing of any adjustment in the Exercise Price and/or the total
number, class, and kind of shares or Other Property issuable upon exercise of this Warrant, which
certificate shall specify the Exercise Price and number, class and kind of shares or Other Property
under this Warrant after giving effect to such adjustment and shall set forth a brief statement of
the facts requiring such adjustment and setting forth the computation by which such adjustment was
made.
7. No Stockholder Rights. This Warrant in and of itself shall not entitle the Holder
to any voting rights or other rights as a stockholder of the Company.
8. Transfer of Warrant. Subject to applicable laws and compliance with Section 4.3
hereof, this Warrant and all rights hereunder are transferable, by the Holder in person
7.
or by duly authorized attorney, upon delivery of this Warrant and the form of assignment
attached hereto to any transferee designated by Holder.
9. Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost, stolen,
mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may
reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or
destroyed. Any such new Warrant shall constitute an original contractual obligation of the
Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any
time enforceable by anyone.
10. Modifications and Waiver. This Warrant and any provision hereof may be changed,
waived, discharged or terminated only by an instrument in writing signed by the Company and the
Holder.
11. Notices, etc. All notices required or permitted hereunder shall be in writing
and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b)
when sent by confirmed facsimile if sent during normal business hours of the recipient, if not,
then on the next business day, (c) five days after having been sent by registered or certified
mail, return receipt requested, postage prepaid, or (d) one business day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of
receipt. All communications shall be sent to the Company at the address listed on the signature
page and to the Holder at the addresses on the Company records, or at such other address as the
Company or Holder may designate by ten days advance written notice to the other party hereto.
12. Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of
and agreement to all of the terms and conditions contained herein.
13. Governing Law. This Warrant and all rights, obligations and liabilities
hereunder shall be governed by the laws of the State of New York without regard to the principles
of conflict of laws.
14. Descriptive Headings. The descriptive headings of the several paragraphs of this
Warrant are inserted for convenience only and do not constitute a part of this Warrant. The
language in this Warrant shall be construed as to its fair meaning without regard to which party
drafted this Warrant.
15. Severability. The invalidity or unenforceability of any provision of this
Warrant in any jurisdiction shall not affect the validity or enforceability of such provision in
any other jurisdiction, or affect any other provision of this Warrant, which shall remain in full
force and effect.
16. Registration Rights. The holder of this Warrant and of the Exercise Shares shall
be entitled to the registration rights and other applicable rights as and to the extent set forth
in the Purchase Agreement.
17. Entire Agreement. This Warrant constitutes the entire agreement between the
parties pertaining to the subject matter contained in it and supersedes all prior and
contemporaneous agreements, representations, and undertakings of the parties, whether oral or
written, with respect to such subject matter.
[Signature Page Follows]
8.
In Witness Whereof, the Company has caused this Warrant to be executed by its duly
authorized officer as of August 5, 2005.
|
|
|
|
|
|
|
|
|
|
|
MannKind Corporation |
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Address: |
|
28903 North Avenue Payne |
|
|
|
|
|
|
|
|
Valencia, CA 91355 |
|
|
|
|
|
|
|
|
Attn: David Thomson |
|
|
|
|
|
|
|
|
Facsimile: (661) 775-2080 |
9.
NOTICE OF EXERCISE
TO: MannKind Corporation
(1) The undersigned hereby elects to (check one box only):
o purchase ___shares of the Common Stock of MannKind Corporation (the
Company) pursuant to the terms of the attached Warrant, and tenders herewith payment of
the exercise price in full for such shares.
o purchase the number of shares of Common Stock of the Company by cashless
exercise pursuant to the terms of the Warrant as shall be issuable upon cashless exercise of
the portion of the Warrant relating to ___shares.
(2) Please issue a certificate or certificates representing said shares of Common Stock in the
name of the undersigned or in such other name as is specified below:
(Name)
(Address)
(3) If the Warrant is not being exercised in full, please issue a certificate representing a
new Warrant evidencing the right of the Holder to purchase the balance of the Exercise Shares
purchasable under the Warrant, such certificate to be registered in the name of the undersigned or
in such other name as is specified below:
(Name)
(Address)
(4) The undersigned represents that (i) the aforesaid shares of Common Stock are being
acquired for the account of the undersigned not with a view to, or for resale in connection with,
the distribution thereof in violation of the Securities Act of 1933, as amended (the Securities
Act) and that the undersigned has no present intention of distributing or reselling such shares in
violation of the Securities Act; (ii) the undersigned is aware of the Companys business affairs
and financial condition and has acquired sufficient information about the Company to reach an
informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned
is experienced in making investments of this type and has such knowledge and background in
financial and business matters that the undersigned is capable of evaluating the merits and risks
of this investment and protecting the undersigneds own interests; (iv) the undersigned understands
that the shares of Common Stock issuable upon exercise of this Warrant must be held indefinitely
unless subsequently registered under the Securities Act or an exemption from such registration is
available, and (v) the undersigned agrees not to make any
1.
disposition of all or any part of the aforesaid shares of Common Stock unless and until there
is then in effect a registration statement under the Securities Act covering such proposed
disposition and such disposition is made in accordance with said registration statement, or the
undersigned has provided the Company with an opinion of counsel satisfactory to the Company,
stating that such registration is not required.
|
|
|
|
|
|
|
|
|
(Date)
|
|
(Signature) |
|
|
|
|
|
|
|
|
(Print name) |
2.
ASSIGNMENT FORM
(To assign the foregoing Warrant, subject to
compliance with section 4.3 hereof, execute this
form and supply required information. Do not use
this form to purchase shares.)
For Value Received, the foregoing Warrant and all rights evidenced thereby are hereby
assigned to
|
|
|
Name: |
|
|
|
|
|
|
|
(Please Print) |
Address: |
|
|
|
|
|
|
|
(Please Print) |
Dated: , 20
|
|
|
|
|
Holders |
|
|
|
|
Signature:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Holders |
|
|
|
|
Address: |
|
|
|
|
|
|
|
|
|
NOTE: The signature to this Assignment Form must correspond with the name as it appears on the
face of the Warrant, without alteration or enlargement or any change whatever. Officers of
corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.
exv99w2
EXHIBIT 99.2
|
|
|
|
Company Contact:
Dick Anderson
Chief Financial Officer
661-775-5302
danderson@mannkindcorp.com
|
|
Investor Relations:
Julie Huang
Financial Dynamics
212-850-5628
jhuang@fd-us.com |
MANNKIND CORPORATION ANNOUNCES $175 MILLION PRIVATE FINANCING
VALENCIA, Calif. (August 3, 2005) MannKind Corporation (Nasdaq NM: MNKD) announced today that it
has entered into a definitive purchase agreement for a $175 million private placement of newly
issued shares of common stock and the concurrent issuance of warrants for the purchase of
additional shares of common stock. Leading institutional investors will invest $87.5 million in the
private placement while Alfred E. Mann, Chairman of the Board, Chief Executive Officer and
principal stockholder of MannKind, will also invest $87.5 million. The financing is scheduled to
close on August 5, 2005. Wachovia Securities and Leerink Swann & Company acted as placement agents
for this transaction.
We are truly pleased that many respected investment firms have participated in this financing. We
believe that these investors recognize that our Technosphere(R) Insulin is a unique and clearly
differentiated product, said Mr. Mann.
Upon the closing of the financing, MannKind will issue approximately 17.1 million shares of common
stock and warrants to purchase up to approximately 3.4 million shares of common stock at an
exercise price of $12.228 per share.
MannKind intends to use the net proceeds from the financing primarily to fund the continuing
development program for the Technosphere(R) Insulin System, which is currently in phase 3 clinical
trials in the U.S. and Europe. Net proceeds from the financing are also expected to be used for the
Companys other product development efforts, working capital, and general corporate purposes.
The shares of common stock and warrants sold in the private placement have not been registered
under the Securities Act of 1933 or state securities laws and may not be offered or sold in the
United States absent registration with the Securities and Exchange Commission or an applicable
exemption from the registration requirements. The shares and warrants were offered and sold only to
accredited investors. MannKind has agreed to file a registration statement with the Securities and
Exchange Commission covering the resale of the shares of common stock issued in the private
placement and the shares of common stock issuable upon exercise of the warrants.
This news release is not an offer to sell or the solicitation of an offer to buy the shares of
common stock or warrants to purchase shares of common stock or any other securities of MannKind.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of
therapeutic products for diseases such as diabetes and cancer. Its lead product, the
Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to
study its safety and efficacy in the treatment of diabetes. For more information on MannKind
Corporation and its technology, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the sale by
MannKind of its securities and the use of proceeds therefrom as well as MannKinds clinical trials
and product candidates. Words such as believes, anticipates, plans, expects, intend,
will, goal, potential and similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon MannKinds current expectations and
involve risks and uncertainties. Actual results and the timing of events could differ materially
from those anticipated in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to MannKinds ability to meet the
closing conditions required for the consummation of the private placement, the progress, timing and
results of clinical trials, difficulties or delays in seeking or obtaining regulatory approval, the
manufacture of the Technosphere(R) Insulin System, competition from other pharmaceutical or
biotechnology companies, MannKinds ability to enter into any collaborations or strategic
partnerships, intellectual property matters and other risks detailed in MannKinds filings with the
SEC, including the Annual Report on Form 10-K for the year ended December 31, 2004 and periodic
reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this cautionary statement, and
MannKind undertakes no obligation to revise or update any forward-looking statements to reflect
events or circumstances after the date of this news release.